Long COVID, formally designated as Post-acute Sequelae of SARS-CoV-2 (PASC), is a complex, multisystem condition characterized by persistent symptoms following resolution of acute SARS-CoV-2 infection. The condition can develop following both mild and severe acute illness and affects an estimated 65 million individuals worldwide.
Conditions with similar clinical presentations that must be differentiated from Long COVID:
Long COVID, formally designated as Post-acute Sequelae of SARS-CoV-2 (PASC), represents a complex, multisystem condition characterized by persistent symptoms following resolution of acute SARS-CoV-2 infection. The World Health Organization defines Long COVID as the continuation or development of new symptoms three months after initial infection, persisting for at least two months without alternative explanation [yang-2023-viral-persistence-abstract]. This condition has emerged as a significant global health challenge, affecting an estimated 65 million individuals worldwide based on conservative incidence estimates of 10% among documented COVID-19 cases [davis-2023-longcovid-review-abstract].
The clinical presentation of Long COVID is remarkably heterogeneous, with more than 200 distinct symptoms documented across multiple organ systems [davis-2023-longcovid-review-abstract]. The most prevalent manifestations include chronic fatigue, cognitive dysfunction colloquially termed "brain fog," post-exertional malaise, dyspnea, cardiovascular symptoms including palpitations and tachycardia, and orthostatic intolerance [komaroff-2023-mecfs-longcovid-abstract]. Notably, the condition can develop following both mild and severe acute illness, may present as a relapsing-remitting course, and can emerge with new symptoms months to years after initial infection [davis-2023-longcovid-review-abstract].
Current understanding implicates multiple, potentially overlapping pathophysiological mechanisms including viral persistence in tissue reservoirs, immune dysregulation and chronic inflammation, autoimmunity, endothelial dysfunction with microvascular clotting, mitochondrial impairment, autonomic nervous system dysfunction, and altered neurotransmitter signaling [davis-2023-longcovid-review-abstract]. Substantial clinical and biological overlap exists with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS; MONDO:0005404) and postural orthostatic tachycardia syndrome (POTS; HP:0031690), suggesting shared underlying mechanisms with these established post-infectious syndromes [komaroff-2023-mecfs-longcovid-abstract].
A growing body of evidence supports viral persistence as a fundamental driver of Long COVID pathophysiology. Multiple autopsy and tissue studies have demonstrated SARS-CoV-2 RNA in diverse anatomical locations extending up to 230 days post-infection, even in individuals with negative nasopharyngeal PCR results [yang-2023-viral-persistence-abstract]. This widespread tissue distribution encompasses the gastrointestinal tract (UBERON:0001555), liver (UBERON:0002107), kidney (UBERON:0002113), brain (UBERON:0000955), blood vessels (UBERON:0001981), lung (UBERON:0002048), and thyroid (UBERON:0002046), suggesting systemic viral dissemination during acute infection with subsequent establishment of tissue reservoirs.
The gastrointestinal tract has emerged as a particularly significant reservoir site. Endoscopic studies with biopsies from small and large intestines detected viral RNA in approximately 30% of specimens from the duodenum, ileum, and colon in Long COVID patients [yang-2023-viral-persistence-abstract]. Specific immunofluorescence has demonstrated involvement of intestinal epithelial cells (CL:0002563) and CD8+ T lymphocytes (CL:0000625). The gut environment may facilitate viral persistence through several mechanisms: the constant exposure to external antigens necessitates immune tolerance to maintain homeostasis, potentially allowing SARS-CoV-2 antigens to evade clearance that would occur in tissues with more robust immune responses [yang-2023-viral-persistence-abstract].
Viral persistence has been mechanistically linked to downstream pathology through sustained type I interferon (IFN) signaling. Wong and colleagues demonstrated that persistent viral components trigger toll-like receptor 3 (TLR3; HGNC:11849)-mediated interferon release, which subsequently impairs intestinal absorption of tryptophan (CHEBI:27897), the essential precursor for serotonin synthesis [wong-2023-serotonin-abstract]. This represents a direct mechanistic connection between viral reservoirs and the serotonin deficiency that may underlie cognitive symptoms in a subset of Long COVID patients.
The question of whether persistent virus represents replication-competent virions or residual viral antigens remains under investigation. While viral RNA detection is well-documented, successful culture of infectious virus from Long COVID patients' tissues has been limited. Nevertheless, the presence of viral proteins appears sufficient to drive ongoing immune activation and tissue damage [yang-2023-viral-persistence-abstract]. Therapeutic strategies targeting viral reservoirs, including nirmatrelvir-ritonavir (Paxlovid), are under investigation in clinical trials for their potential to alleviate Long COVID symptoms through viral clearance.
Immunological studies have revealed persistent immune activation and inflammation extending well beyond the acute infection period. Yin and colleagues performed comprehensive immunological profiling on individuals at least eight months post-infection, demonstrating that Long COVID patients exhibit systemic inflammation and immune dysregulation distinct from fully recovered controls [yin-2024-tcell-dysregulation-abstract]. This dysfunction manifests through multiple immune cell populations and signaling pathways.
T cell abnormalities represent a hallmark of Long COVID immunopathology. Long COVID individuals display increased frequencies of CD4+ T cells (CL:0000624) expressing tissue-migration markers, indicating cells poised to traffic to sites of inflammation [yin-2024-tcell-dysregulation-abstract]. Concurrently, SARS-CoV-2-specific CD8+ T cells (CL:0000625) exhibit exhaustion phenotypes characterized by sustained expression of inhibitory receptors including programmed cell death protein 1 (PD-1; HGNC:8760), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3; HGNC:18437), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4; HGNC:2505). T cell exhaustion results from prolonged antigenic stimulation and is associated with impaired proliferative capacity, reduced effector functions, diminished cytokine secretion, and transcriptional reprogramming [yin-2024-tcell-dysregulation-abstract].
Humoral immunity also demonstrates dysregulation in Long COVID. Patients exhibit elevated SARS-CoV-2-specific antibody levels compared to recovered individuals, along with evidence of mis-coordination between T cell and B cell (CL:0000236) responses [yin-2024-tcell-dysregulation-abstract]. This improper crosstalk between cellular and humoral adaptive immunity may contribute to sustained immune dysfunction and failure to achieve homeostatic resolution.
Pathway analysis reveals persistent upregulation of pro-inflammatory signaling cascades including the JAK-STAT pathway (GO:0007259), interleukin-6 signaling (GO:0070102), complement activation (GO:0006956), and metabolic pathways associated with immune activation [yin-2024-tcell-dysregulation-abstract]. Elevated circulating levels of pro-inflammatory cytokines including interferon-alpha (IFN-α; HGNC:5417), tumor necrosis factor-alpha (TNF-α; HGNC:11892), granulocyte colony-stimulating factor (G-CSF; HGNC:2438), interleukin-17A (IL-17A; HGNC:5981), interleukin-6 (IL-6; HGNC:6018), interleukin-1 beta (IL-1β; HGNC:5992), and interleukin-13 (IL-13; HGNC:5973) have been documented in Long COVID patients [kavanagh-2022-brainfog-neuroinflammation-abstract]. Persistent IL-6 dysregulation specifically correlates with generalized fatigue (HP:0012378), sleep disturbance (HP:0002360), depression (HP:0000716), and anxiety (HP:0000739).
Autoimmune phenomena have been identified in subsets of Long COVID patients. Autoantibodies targeting gangliosides—glycolipids highly expressed on peripheral nerves—are characteristic of post-infectious Guillain-Barré syndrome and have been identified in individuals with sensory loss and muscle weakness following COVID-19. Additionally, antibodies targeting adrenergic and muscarinic receptors are associated with POTS and autonomic dysfunction, likely reflecting molecular mimicry where immune responses directed against SARS-CoV-2 cross-react with host tissues. Anti-myelin oligodendrocyte glycoprotein (MOG) and anti-NMDA receptor antibodies suggest autoimmunity may sustain central nervous system inflammation and cognitive decline in some patients.
The NLRP3 inflammasome represents a critical innate immune pathway implicated in both acute COVID-19 hyperinflammation and the chronic inflammatory state of Long COVID [yin-2023-nlrp3-inflammasome-abstract]. The NLRP3 inflammasome (HGNC:16400) is a multiprotein complex that, when activated, drives inflammatory macrophage (CL:0000235) activation through caspase-1 (CASP1; HGNC:1499), which processes pro-inflammatory cytokines IL-1β (HGNC:5992) and IL-18 (HGNC:5986) into their mature, secreted forms.
Inflammasome activation follows a two-step process involving priming and activation signals. During priming, pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) are recognized by Toll-like receptors (TLRs; HGNC:11850), initiating activation of the transcription factor nuclear factor kappa B (NF-κB; HGNC:7794) through complex intracellular signaling cascades [yin-2023-nlrp3-inflammasome-abstract]. NF-κB subsequently upregulates transcription of NLRP3 inflammasome components, including NLRP3 itself, pro-IL-1β, and pro-caspase-1, preparing the cell for inflammatory activation.
SARS-CoV-2-derived double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA) are sensed by endosomal TLR3 (HGNC:11849) and TLR7 (HGNC:15631), as well as by the cytosolic sensor MDA5 (IFIH1; HGNC:18873), which upregulate NLRP3 components via NF-κB (GO:0038061). A second signal from viral components triggers NLRP3 oligomerization and inflammasome assembly. Viral viroporins including ORF3a, envelope (E) protein, and nucleocapsid (N) protein can directly activate NLRP3, as can host-derived danger signals such as complement protein C5a-triggered reactive oxygen species, oxidized phospholipids from lung surfactant, or ATP (CHEBI:15422) released from dying cells [yin-2023-nlrp3-inflammasome-abstract].
Activated caspase-1 also cleaves gasdermin D (GSDMD; HGNC:25697), leading to formation of membrane pores and pyroptotic cell death (GO:0070269), a highly inflammatory form of programmed cell death characterized by cellular swelling, membrane rupture, and release of intracellular contents. Pyroptosis amplifies inflammation by releasing DAMPs and pro-inflammatory cytokines, potentially establishing a feed-forward loop contributing to persistent inflammation in Long COVID.
Recent research has demonstrated that NLRP3 inflammasome biomarkers exhibit robust correlation with Long COVID severity, with reduced oxygen saturation during acute illness predicting increased inflammasome activity and subsequent physio-affective symptoms [yin-2023-nlrp3-inflammasome-abstract]. Strategic targeting of the NLRP3 inflammasome through pharmacological inhibitors may therefore be beneficial in addressing both acute COVID-19 and prolonged symptoms associated with Long COVID.
Vascular pathology represents a potentially unifying mechanism connecting diverse Long COVID manifestations. Kell and Pretorius have proposed that amyloid fibrin microclots—termed "fibrinaloids"—play a central role in Long COVID pathophysiology [kell-2022-microclots-abstract]. These anomalous fibrin deposits form when fibrinogen (HGNC:3661) polymerizes into amyloid-like structures that resist normal fibrinolysis (GO:0042730). The SARS-CoV-2 spike protein has been shown to directly induce formation of these fibrinaloid structures [turner-2023-coagulation-abstract].
The pathophysiological significance of microclots relates to their capacity to obstruct capillaries (UBERON:0001982), thereby impairing oxygen (CHEBI:25805) delivery to tissues [kell-2022-microclots-abstract]. This mechanism could potentially explain the diverse symptomatology of Long COVID, as impaired tissue oxygenation would manifest differently depending on which organ systems are most affected. Detection of microclots using thioflavin T (CHEBI:52377) staining—which fluoresces upon binding amyloid structures—has demonstrated elevated microclot prevalence in Long COVID patients compared to recovered controls.
Endothelial dysfunction (HP:0025032) constitutes another critical vascular abnormality. Virus-induced endotheliitis during acute infection disrupts normal endothelial function, initiating aberrant coagulation physiology [turner-2023-coagulation-abstract]. The endothelium (CL:0000115) plays essential roles in regulating vascular tone, preventing thrombosis, and maintaining blood-brain barrier integrity. Persistent endothelial dysfunction promotes a pro-thrombotic state characterized by hyperactivated platelets (CL:0000233) and ongoing microclot formation.
Multiple contributing factors converge on this thrombotic endothelialitis, including viral persistence, chronic inflammation, metabolic dysregulation, and autoimmunity [turner-2023-coagulation-abstract]. These abnormalities of blood vessels and coagulation affect every organ system and may represent a unifying pathway for Long COVID symptoms. Therapeutic approaches targeting this pathway include anticoagulation with the aim of restoring coagulation balance rather than "thinning the blood," though clinical evidence for efficacy remains under investigation.
A landmark 2023 study published in Cell identified peripheral serotonin (CHEBI:28790) reduction as a mechanistic link connecting viral persistence, inflammation, coagulopathy, and cognitive dysfunction in Long COVID [wong-2023-serotonin-abstract]. Serotonin levels were substantially reduced during acute SARS-CoV-2 infection and remained depressed in patients with PASC, while fully recovered individuals showed normalization of serotonin levels.
Three mechanisms contribute to serotonin depletion in Long COVID. First, viral infection and type I interferon-driven inflammation reduce intestinal absorption of tryptophan (CHEBI:27897), the essential amino acid precursor for serotonin synthesis [wong-2023-serotonin-abstract]. Second, platelet hyperactivation and thrombocytopenia (HP:0001873) deplete circulating serotonin stores, as platelets serve as the primary peripheral serotonin reservoir. Third, enhanced monoamine oxidase (MAO; HGNC:6833)-mediated serotonin turnover accelerates serotonin degradation.
Critically, the serotonin deficiency occurs peripherally rather than centrally, yet still produces cognitive symptoms. Wong and colleagues demonstrated that peripheral serotonin reduction impairs vagus nerve (UBERON:0001759) activity, which subsequently affects hippocampal (UBERON:0002421) responses and memory function [wong-2023-serotonin-abstract]. This gut-brain axis connection explains how intestinal pathology could produce neurocognitive manifestations without requiring direct central nervous system infection.
The therapeutic implications are significant: in mouse models, serotonin levels could be restored and memory impairment reversed through treatment with serotonin precursors such as 5-hydroxytryptophan (5-HTP; CHEBI:17780) or selective serotonin reuptake inhibitors (SSRIs) [wong-2023-serotonin-abstract]. This provides a potential pharmacological target for the cognitive symptoms affecting many Long COVID patients, though clinical trials in humans are needed.
Mitochondrial dysfunction has emerged as a central mechanism underlying the chronic fatigue, exercise intolerance, and post-exertional malaise characteristic of Long COVID [molnar-2024-mitochondria-abstract]. These symptoms suggest systemic alterations in cellular energy metabolism extending beyond the initial viral pathology.
Key findings demonstrate reduced adenosine triphosphate (ATP; CHEBI:15422) production in Long COVID patients, with transmission electron microscopy revealing structural mitochondrial abnormalities including significant swelling, disrupted cristae, and irregular morphology indicating severe mitochondrial distress [molnar-2024-mitochondria-abstract]. SARS-CoV-2 infection shifts cellular metabolism toward glycolysis (GO:0006096) due to impaired oxidative phosphorylation (GO:0006119), a phenomenon reminiscent of the Warburg effect in cancer cells.
The SARS-CoV-2 spike protein directly compromises mitochondrial function by decreasing basal mitochondrial respiration, reducing ATP production, and increasing glucose-induced glycolysis [molnar-2024-mitochondria-abstract]. This shifts energy production toward less efficient anaerobic pathways, reducing overall cellular energy availability. Additionally, infection causes prolonged disruptions in phosphocreatine (CHEBI:17287) metabolism, a key process facilitating ATP regeneration that manifests clinically as fatigue and diminished physical capacity.
Heightened oxidative stress accompanies mitochondrial dysfunction, with increased production of reactive oxygen species (CHEBI:26523) causing oxidative damage to cellular components [molnar-2024-mitochondria-abstract]. Disrupted mitochondrial biogenesis (GO:0000959) and impaired mitochondrial-nuclear signaling compound these effects, preventing normal mitochondrial quality control and replacement.
Therapeutic strategies targeting mitochondrial function include supplementation with coenzyme Q10 (CoQ10; CHEBI:16389), which serves as an essential electron carrier in the respiratory chain; N-acetylcysteine (NAC; CHEBI:7452) to restore glutathione levels and combat oxidative stress; creatine (CHEBI:16919) to enhance ATP buffering capacity; and B-complex vitamins serving as essential mitochondrial cofactors [molnar-2024-mitochondria-abstract]. These parallels with ME/CFS—where mitochondrial impairment has been extensively documented—suggest shared pathophysiology and potentially shared therapeutic approaches.
Autonomic dysfunction represents one of the most prevalent and debilitating manifestations of Long COVID, affecting approximately 60-80% of patients based on standardized autonomic symptom assessments [dani-2021-autonomic-dysfunction-abstract]. Postural orthostatic tachycardia syndrome (POTS; HP:0031690) and orthostatic hypotension (HP:0001278) are the most commonly diagnosed autonomic disorders in this population.
POTS is characterized by an excessive heart rate increase of 30 beats per minute or more upon standing for greater than 30 seconds (40 bpm in adolescents aged 12-19), occurring in the absence of orthostatic hypotension [dani-2021-autonomic-dysfunction-abstract]. Symptoms include breathlessness (HP:0002094), chest pain (HP:0100749), palpitations (HP:0001962), and orthostatic intolerance (HP:0003474), which can severely impair daily functioning and quality of life.
Multiple mechanisms likely contribute to post-COVID autonomic dysfunction. Direct viral neurotropism may damage autonomic ganglia, while immune-mediated mechanisms including autoantibodies against alpha/beta-adrenoceptors (HGNC:285, HGNC:286) and muscarinic receptors (HGNC:7220) have been implicated [dani-2021-autonomic-dysfunction-abstract]. Cytokine-mediated inflammation during acute infection may trigger chronic neuronal dysregulation. Hypovolemia from inadequate fluid intake or renal dysregulation, and deconditioning effects from prolonged illness and reduced activity, also contribute.
Management strategies encompass both non-pharmacological and pharmacological approaches [dani-2021-autonomic-dysfunction-abstract]. Conservative measures include increased fluid and salt intake to expand intravascular volume, compression stockings to reduce venous pooling, and careful reconditioning programs. Pharmacological options include beta-blockers and ivabradine to reduce heart rate, midodrine as an alpha-1 agonist to increase peripheral vascular resistance, and fludrocortisone to expand plasma volume through mineralocorticoid effects.
Cognitive dysfunction, commonly described as "brain fog," represents one of the most disabling Long COVID symptoms, with meta-analyses indicating approximately 34% of COVID-19 survivors experience cognitive deficits persisting beyond six months [kavanagh-2022-brainfog-neuroinflammation-abstract]. Neurological symptoms including memory impairment (HP:0002354), attention deficits (HP:0007018), and executive dysfunction reflect underlying neuroinflammatory processes.
Neuroinflammation in Long COVID involves multiple interconnected mechanisms. Microglial (CL:0000129) activation represents a central feature: these resident immune cells of the central nervous system, when chronically activated, release inflammatory mediators that disrupt neural network function and impair synaptic plasticity (GO:0048167) [kavanagh-2022-brainfog-neuroinflammation-abstract]. Inflammatory cytokines including IL-6 and TNF-α reduce long-term potentiation (LTP) and long-term depression (LTD)—the cellular substrates of learning and memory—while also inhibiting neurogenesis (GO:0022008) and impairing dendritic sprouting.
Blood-brain barrier (BBB; UBERON:0000120) disruption has been demonstrated in Long COVID patients with cognitive impairment using dynamic contrast-enhanced MRI [kavanagh-2022-brainfog-neuroinflammation-abstract]. Persistent systemic inflammation drives cytokine production that, combined with increased BBB permeability, allows inflammatory mediators to penetrate the brain parenchyma and sustain neuroinflammation. A more porous BBB may also permit limited viral invasion of neural tissue.
Notably, the relative contributions of systemic inflammation, direct viral effects, and vascular mechanisms to neurological symptoms remain under investigation. The serotonin depletion mechanism identified by Wong and colleagues provides an alternative explanation whereby peripheral metabolic changes impair hippocampal function through vagal nerve pathways without requiring direct brain pathology [wong-2023-serotonin-abstract]. Different mechanisms may predominate in different patient subgroups, highlighting the heterogeneity of Long COVID neurology.
Mast cell activation syndrome (MCAS) has been implicated in Long COVID pathophysiology based on substantial symptom overlap and therapeutic responses to histamine receptor blockade [salvucci-2023-antihistamines-abstract]. Mast cells (CL:0000097), located abundantly in the pulmonary perivascular space and other tissues, express angiotensin-converting enzyme 2 (ACE2; HGNC:13557) receptors and represent frontline responders to SARS-CoV-2 infection.
Mast cell degranulation releases numerous pro-inflammatory mediators including histamine (CHEBI:18295), platelet-activating factor (CHEBI:44811), heparin (CHEBI:28304), tryptase (HGNC:14118), prostaglandins (CHEBI:26333), leukotrienes (CHEBI:25029), and chemokines including IL-1β and IL-6 [salvucci-2023-antihistamines-abstract]. In Long COVID, persistent inflammatory states may activate specific mast cell genes, leading to abnormal mast cell activation control and chronic mediator release.
The symptom overlap between MCAS and Long COVID includes fatigue, cognitive dysfunction, gastrointestinal disturbances, respiratory symptoms including shortness of breath, palpitations, and musculoskeletal pain [salvucci-2023-antihistamines-abstract]. Clinical evidence supports this mechanistic link: treatment of Long COVID patients with histamine H1 and H2 receptor antagonists (fexofenadine 180 mg/day and famotidine 40 mg/day) produced significant improvement in fatigue, brain fog, cardiovascular symptoms, and gastrointestinal manifestations, with complete symptom resolution in 29% of treated patients [salvucci-2023-antihistamines-abstract].
Histamine-dependent mechanisms may also mediate T cell disorders in Long COVID, suggesting crosstalk between mast cell activation and adaptive immune dysfunction. Diagnostic markers for mast cell activation include serum tryptase, urinary N-methylhistamine, and urinary prostaglandin D2, which may help identify patients likely to benefit from mast cell-targeted therapies.
Emerging evidence implicates gut microbiome alterations as both a consequence of SARS-CoV-2 infection and a contributing factor to Long COVID pathogenesis [lau-2025-gut-microbiome-abstract]. Patients with Long COVID consistently exhibit reduced microbial diversity, depletion of beneficial short-chain fatty acid (SCFA; CHEBI:26666)-producing species including Faecalibacterium prausnitzii and Bifidobacterium spp., and enrichment of proinflammatory taxa including Ruminococcus gnavus, Bacteroides vulgatus, and Veillonella. At the phylum level, Long COVID patients demonstrate lower abundance of Actinobacteria and Firmicutes with higher Bacteroidetes compared to healthy controls.
Multiple mechanisms link gut dysbiosis to Long COVID symptomatology. Impaired SCFA metabolism reduces anti-inflammatory signaling, as SCFAs including butyrate (CHEBI:17968), propionate (CHEBI:17272), and acetate (CHEBI:30089) normally suppress inflammatory gene expression and maintain intestinal barrier integrity (GO:0060548) [lau-2025-gut-microbiome-abstract]. Tryptophan depletion—resulting from both reduced microbial production and impaired intestinal absorption—contributes to serotonin deficiency as described above. Microbial translocation across a compromised intestinal barrier allows bacterial products including lipopolysaccharide (LPS; CHEBI:16412) to enter systemic circulation, driving chronic low-grade inflammation.
ACE2 dysfunction provides a mechanistic link between SARS-CoV-2 infection and gut dysbiosis. Persistent viral presence leads to internalization of the ACE2-B0AT1 (SLC6A19; HGNC:23089) complex in intestinal epithelial cells, resulting in decreased tryptophan absorption [lau-2025-gut-microbiome-abstract]. This impairs mTOR (MTOR; HGNC:3942) pathway activation, which is required for antimicrobial peptide (AMP) production and tight junction formation. Reduced AMP levels alter commensal bacterial composition, while compromised tight junctions permit bacterial translocation, establishing a self-reinforcing cycle of dysbiosis and barrier dysfunction.
The gut-brain axis provides a pathway through which intestinal dysbiosis influences neurological symptoms. Decreased SCFA production impairs enteroendocrine cell function and reduces vagal nerve stimulation, potentially contributing to neuroinflammation [lau-2025-gut-microbiome-abstract]. Altered hypothalamic-pituitary-adrenal (HPA) axis function, reduced neurotransmitter synthesis, and systemic inflammation all may contribute to the cognitive and psychiatric manifestations of Long COVID through gut-brain communication.
Therapeutic modulation of the gut microbiome shows promise for Long COVID management. Clinical trials have demonstrated that probiotics, prebiotics, and fecal microbiota transplantation (FMT) can improve multiple Long COVID symptoms including fatigue, memory impairment, concentration difficulties, gastrointestinal disturbances, and sleep/mood disturbances [lau-2025-gut-microbiome-abstract]. A synbiotic preparation designated SIM01, containing Bifidobacterium adolescentis, B. bifidum, and B. longum, has been shown to accelerate SARS-CoV-2 antibody formation, reduce nasopharyngeal viral load and pro-inflammatory markers, and restore gut dysbiosis, with significant alleviation of Long COVID symptoms at six months post-infection compared to placebo.
Post-COVID-19 pulmonary fibrosis (HP:0002206) represents the most severe long-term respiratory complication of SARS-CoV-2 infection [zheng-2023-pulmonary-fibrosis-abstract]. Approximately 20-30% of patients recovering from moderate to severe COVID-19 pneumonia develop radiographic or physiologic evidence of fibrotic lung changes within three to six months of recovery, with some studies documenting respiratory impairment persisting up to three years post-infection. This burden is particularly pronounced in individuals who required mechanical ventilation or experienced acute respiratory distress syndrome (ARDS).
The pathogenesis of post-COVID pulmonary fibrosis involves interplay between viral injury, aberrant repair, and persistent inflammation. SARS-CoV-2 directly damages alveolar epithelial cells (CL:0000066), particularly type II alveolar cells (AT2; CL:0002062) which are critical for surfactant production and alveolar regeneration [zheng-2023-pulmonary-fibrosis-abstract]. Injured AT2 cells may undergo aberrant repair pathways characterized by epithelial-mesenchymal transition (GO:0001837), contributing to fibroblast activation and myofibroblast differentiation.
Key molecular drivers of pulmonary fibrosis include transforming growth factor-beta (TGF-β; HGNC:11766), which promotes fibroblast proliferation, extracellular matrix deposition, and collagen (CHEBI:3815) synthesis [zheng-2023-pulmonary-fibrosis-abstract]. Interleukin-6 (IL-6) contributes to both inflammatory and fibrogenic processes. Persistent infiltration of macrophages and monocytes—a characteristic feature of SARS-CoV-2 pulmonary pathology—creates a profibrotic microenvironment through sustained release of growth factors and cytokines.
Histopathological findings in severe COVID-19 include progressive loss of epithelial-endothelial integrity, septal capillary injury, complement deposition, intravascular viral antigen deposition, and localized intravascular coagulation [zheng-2023-pulmonary-fibrosis-abstract]. Neutrophil extracellular trap (NET) formation contributes to airway inflammation and epithelial injury. These pathological changes may be exacerbated by ventilator-induced lung injury (VILI) in patients requiring mechanical ventilation.
Risk factors for post-COVID pulmonary fibrosis include advanced age, male sex, and severity of acute COVID-19 illness [zheng-2023-pulmonary-fibrosis-abstract]. Unlike idiopathic pulmonary fibrosis (IPF), post-COVID fibrosis may demonstrate partial resolution over time in some patients, though others experience progressive disease. Therapeutic approaches under investigation include established antifibrotic agents (pirfenidone, nintedanib), corticosteroids, mesenchymal stem cell therapy, and combination approaches targeting both inflammatory (IL-6) and immunosuppressive (CD47) pathways.
Reactivation of latent herpesviruses, particularly Epstein-Barr virus (EBV), has been associated with Long COVID development and specific symptom clusters. EBV is a gamma-herpesvirus that establishes lifelong latency in B cells following primary infection, which occurs in over 95% of healthy adults. Various stressors including acute infections can trigger viral reactivation from the dormant state.
Studies have demonstrated that EBV reactivation during early SARS-CoV-2 infection predicts subsequent Long COVID development. Research found that 66.7% of Long COVID patients showed evidence of EBV reactivation, with detection of EBV DNA in throat washings in 50% of Long COVID patients compared to only 20% of fully recovered controls. EBV reactivation shows particularly strong association with three Long COVID symptoms: fatigue, memory deficits, and persistent mucus cough, with odds increasing by 150-250% in those with reactivated EBV.
Multiple herpesviruses may contribute to Long COVID pathology including human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV). The postulated mechanisms linking COVID-19 with herpesvirus reactivation and subsequent autoimmunity include direct stimulation by SARS-CoV-2 infection, release of inflammatory substances from infected cells, and heme-mediated reactivation. Dysregulated herpesvirus infection can trigger or promote autoimmune responses through various mechanisms.
These findings have therapeutic implications: antiviral medications effective against herpesviruses, such as ganciclovir and valacyclovir, have shown some efficacy in reducing mortality in severe COVID-19 and may warrant investigation for Long COVID treatment in patients with documented herpesvirus reactivation.
Long COVID manifests through multiple distinct yet overlapping phenotypes that likely reflect different predominant pathophysiological mechanisms. The major clinical phenotype clusters include: (1) fatigue-dominant presentations with post-exertional malaise resembling ME/CFS; (2) cardiovascular/autonomic phenotypes characterized by POTS, palpitations, and orthostatic intolerance; (3) neurocognitive phenotypes with prominent brain fog, memory impairment, and concentration difficulties; (4) respiratory phenotypes with persistent dyspnea and reduced exercise capacity; and (5) inflammatory/pain phenotypes with myalgias, arthralgias, and systemic symptoms.
Post-exertional malaise (PEM; HP:0030973) deserves particular attention as a distinguishing feature shared with ME/CFS. PEM involves worsening of symptoms following minimal physical or cognitive exertion, typically beginning 12-48 hours after the triggering activity and lasting for days or longer [komaroff-2023-mecfs-longcovid-abstract]. Proposed mechanisms include skeletal muscle tissue damage, intramuscular immune cell infiltration, intrinsic mitochondrial dysfunction, endothelial abnormalities, and a shift toward more glycolytic muscle fiber phenotypes. Approximately 58% of Long COVID patients meet ME/CFS diagnostic criteria, underscoring the substantial overlap between these conditions.
Disease progression in Long COVID varies considerably among individuals. Some patients experience gradual improvement over months, while others develop persistent symptoms lasting years. A subset experiences a relapsing-remitting course with periods of relative wellness punctuated by symptom flares. New symptoms may emerge months after initial infection, suggesting ongoing pathological processes or delayed manifestation of initial damage. Risk factors for developing Long COVID include female sex, type 2 diabetes (MONDO:0005148), pre-existing autoimmune conditions, and evidence of EBV reactivation during acute infection [davis-2023-longcovid-review-abstract].
Despite substantial progress in characterizing Long COVID pathophysiology, numerous critical questions remain unresolved. First, the relative contribution of each proposed mechanism—viral persistence, immune dysregulation, autoimmunity, vascular pathology, and metabolic dysfunction—to the overall disease burden remains unclear, and different mechanisms may predominate in different patient subgroups, suggesting the need for biomarker-based patient stratification. Second, the determinants of Long COVID risk and resilience are incompletely understood; why do some individuals develop persistent symptoms while others with similar acute illness recover fully?
The relationship between viral persistence and symptoms requires further elucidation: specifically, whether persistent viral antigens actively drive pathology or represent epiphenomena, and whether antiviral therapy can improve outcomes in established Long COVID. The microclot hypothesis, while compelling, requires independent replication and clinical trial evidence demonstrating therapeutic benefit from anticoagulation. Similarly, the serotonin depletion mechanism identified in a single study needs confirmation across larger cohorts and diverse populations.
Neurological mechanisms warrant particular attention given the prevalence and disability associated with cognitive symptoms. The conflicting evidence regarding neuroinflammation versus peripheral metabolic effects (serotonin depletion) in brain fog suggests either mechanism heterogeneity or the need for more sensitive detection methods. The potential role of viral infection of neural tissue, as distinct from indirect inflammatory effects, remains controversial.
From a therapeutic perspective, no treatments have demonstrated efficacy in large randomized controlled trials. Promising candidates including antivirals (nirmatrelvir-ritonavir), immunomodulators, anticoagulants, mitochondrial supplements, and serotonergic agents require rigorous evaluation. The optimal approach to rehabilitation, particularly regarding exercise in patients with post-exertional malaise, needs clarification to avoid iatrogenic harm.
Finally, the evolution of Long COVID in the context of population immunity (from vaccination and prior infection) and viral evolution (emergence of new variants) requires ongoing surveillance. Whether Long COVID risk differs by variant, vaccination status, or number of prior infections has implications for public health policy and individual risk communication.
davis-2023-longcovid-review: Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023 Mar;21(3):133-146. DOI: 10.1038/s41579-022-00846-2. PMID: 36639608. PMCID: PMC9839201. URL: https://www.nature.com/articles/s41579-022-00846-2
yin-2024-tcell-dysregulation: Yin K, Peluso MJ, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nature Immunology. 2024 Feb;25(2):218-225. DOI: 10.1038/s41590-023-01724-6. PMID: 38212464. PMCID: PMC10834368. URL: https://pubmed.ncbi.nlm.nih.gov/38212464/
wong-2023-serotonin: Wong AC, Devason AS, Umana IC, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023 Oct 26;186(22):4851-4867.e20. DOI: 10.1016/j.cell.2023.09.013. PMID: 37848036. URL: https://pubmed.ncbi.nlm.nih.gov/37848036/
kell-2022-microclots: Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochemical Journal. 2022 Feb 23;479(4):537-559. DOI: 10.1042/BCJ20220016. PMID: 35195253. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8883497/
turner-2023-coagulation: Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends in Endocrinology and Metabolism. 2023 Jun;34(6):321-344. DOI: 10.1016/j.tem.2023.03.002. PMID: 37080828. URL: https://pubmed.ncbi.nlm.nih.gov/37080828/
molnar-2024-mitochondria: Molnar T, Lehoczki A, Fekete M, et al. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. GeroScience. 2024 Apr 26. DOI: 10.1007/s11357-024-01165-5. PMID: 38668888. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11336094/
yang-2023-viral-persistence: Yang C, Zhao H, Espín E, Tebbutt SJ. Association of SARS-CoV-2 infection and persistence with long COVID. The Lancet Respiratory Medicine. 2023 Jun;11(6):504-506. DOI: 10.1016/S2213-2600(23)00142-X. PMID: 37178694. PMCID: PMC10171832. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10171832/
komaroff-2023-mecfs-longcovid: Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Frontiers in Medicine. 2023 Jun 2;10:1187163. DOI: 10.3389/fmed.2023.1187163. PMID: 37342500. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10278546/
dani-2021-autonomic-dysfunction: Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clinical Medicine. 2021 Jan;21(1):e63-e67. DOI: 10.7861/clinmed.2020-0896. PMID: 33243837. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7850225/
kavanagh-2022-brainfog-neuroinflammation: Kavanagh E. Long Covid brain fog: a neuroinflammation phenomenon? Oxford Open Immunology. 2022 Sep 27;3(1):iqac007. DOI: 10.1093/oxfimm/iqac007. PMID: 36846556. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9914477/
salvucci-2023-antihistamines: Salvucci F, Codella R, Coppola A, et al. Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. Frontiers in Cardiovascular Medicine. 2023 Jul 17;10:1202696. DOI: 10.3389/fcvm.2023.1202696. PMID: 37529714. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10388239/
yin-2023-nlrp3-inflammasome: Yin M, Marrone L, Peace CG, O'Neill LAJ. NLRP3, the inflammasome and COVID-19 infection. QJM: An International Journal of Medicine. 2023 Jan 20;116(7):502-507. DOI: 10.1093/qjmed/hcad011. PMID: 36661317. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10382191/
lau-2025-gut-microbiome: Lau RI, Su Q, Ng SC. Long COVID and gut microbiome: insights into pathogenesis and therapeutics. Gut Microbes. 2025 Dec;17(1):2457495. DOI: 10.1080/19490976.2025.2457495. PMID: 39854158. URL: https://pubmed.ncbi.nlm.nih.gov/39854158/
zheng-2023-pulmonary-fibrosis: Zheng Z, Peng F, Zhou Y. Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19? Chinese Medical Journal Pulmonary and Critical Care Medicine. 2023 Jan 16;1(2):77-83. DOI: 10.1016/j.pccm.2022.12.002. PMID: 37388822. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9988550/
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on the pathophysiology of Long COVID. Focus on the molecular and cellular mechanisms underlying disease progression.
Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs
Definition / case concept. Long COVID (PASC) is a heterogeneous syndrome of persistent or new symptoms after acute SARS‑CoV‑2 infection. The Collegium Internationale Allergologicum update notes a clinical definition consistent with WHO framing (symptoms beginning within ~3 months and persisting ≥2 months) and emphasizes multi-organ involvement and immune mechanisms (e.g., persistent reservoir, metabolic reprogramming, virus reactivation, autoimmunity, microbiome dysbiosis). (untersmayr2024immunemechanismsunderpinning pages 2-2, untersmayr2024immunemechanismsunderpinning pages 1-2)
Scale of the problem. A conservative estimate of ~10% of infections developing long COVID is summarized in a 2024 immune review, translating to ≥65 million people worldwide. (untersmayr2024immunemechanismsunderpinning pages 1-2)
Heterogeneity / endotypes. A major current concept is that PASC is not a single entity but comprises biological subtypes. Serum proteomics identifies an “inflammatory” subcategory characterized by type II interferon (IFN‑γ) and TNF/NF‑κB pathway activity and a second inflammatory pattern involving neutrophil activation and type I IFN–associated proteins. (talla2023persistentserumprotein pages 6-7, talla2023persistentserumprotein pages 1-2)
Long COVID pathophysiology is best supported by converging evidence for (A) viral persistence/antigenemia, (B) chronic immune activation/dysregulation and autoimmunity, (C) endothelial dysfunction/barrier injury with thromboinflammation, and (D) metabolic/mitochondrial dysfunction with organ-specific manifestations (notably skeletal muscle in post‑exertional malaise).
Tissue reservoirs and prolonged antigen. A high-impact 2023 Nature Immunology review synthesizes evidence that SARS‑CoV‑2 RNA/protein can persist in multiple tissues for months after acute infection and that persistence can occur despite negative nasopharyngeal testing. It highlights detection windows such as 31–230 days, including subgenomic RNA (marker of recent replication) at day 99, and reports of viral RNA in 80% of lung samples up to 174 days in one study. (proal2023sarscov2reservoirin pages 4-6)
Upper airway and GI persistence durations. A 2024 review summarizes that SARS‑CoV‑2 RNA has been isolated up to 3 months in the upper respiratory tract, 2 months in serum, and 126 days in stool. (gusev2024exploringthepathophysiology pages 2-4)
Prospective evidence for persistent nucleocapsid antigenemia in PASC. In a prospective cohort (Aug 2022–Jul 2023), 29/57 (51%) met a questionnaire-based PASC definition; nucleocapsid protein (NP) antigen was higher in PASC at 3 months (median 5.49 ng/mL vs 0.59 ng/mL; P=0.022) despite being lower during acute illness (median 1.58 ng/mL vs 12.42 ng/mL; P=0.045). (ra2024viralimmunologicand pages 2-4)
Mechanistic implications. Peluso & Deeks (Cell 2024) emphasize that higher acute viral burden, RNAemia, and prolonged clearance correlate with long COVID risk and that interventions limiting early viral replication (vaccines; antivirals) provide indirect evidence that reducing acute viral burden may reduce long-term sequelae. (peluso2024mechanismsoflong pages 6-8)
Proteomic inflammatory endotype: IFN‑γ and TNF/NF‑κB. A 2023 Nature Communications longitudinal serum proteomics study identifies an inflammatory PASC subgroup with dominant enrichment of “Type II interferon signaling and canonical NF‑κB signaling (particularly associated with TNF)”. (talla2023persistentserumprotein pages 1-2)
A simple biomarker panel for inflammatory PASC stratification. The same study proposes a 3‑protein panel (CCL7, CD40LG, S100A12) with AUROC 0.865 (95% CI 0.765–0.966) training and 0.788 (95% CI 0.590–0.985) test. (talla2023persistentserumprotein pages 10-11)
Prospective cytokine differences accompanying antigenemia. In the JKMS 2024 cohort, among 33 cytokines measured, IL‑2, IL‑17A, VEGF, RANTES (CCL5), sCD40L, IP‑10 (CXCL10), I‑TAC (CXCL11), and granzyme A were reported as significantly elevated in the PASC group at 1 and/or 3 months. (ra2024viralimmunologicand pages 5-6, ra2024viralimmunologicand pages 1-2)
Inflammasome and persistent immune activation. A 2024 review emphasizes chronic low‑grade inflammation and notes NLRP3 inflammasome activation among implicated mechanisms. (gusev2024exploringthepathophysiology pages 2-4)
Endothelial barrier injury as a central organizing mechanism. An Angiogenesis 2024 review states that endothelial injury is observed in acute and convalescent COVID and that endothelial dysfunction contributes to long COVID; it reports persistent elevation of D‑dimer, factor VIII, thrombin, vWF, ICAM‑1 and IL‑6 detectable even one year after recovery, alongside persistent glycocalyx shedding and circulating endothelial cells. (wu2024damagetoendothelial pages 1-2)
Mechanistic drivers of endothelial pathology. The same review links endothelial dysfunction to inflammatory cytokines (IL‑6, IL‑1, TNF), activated platelets, increased thrombin, NETs, and complement, producing a prothrombotic endothelial phenotype; spike can damage endothelial cells via ACE2 downregulation. (wu2024damagetoendothelial pages 1-2)
Severe post‑COVID ARDS: persistent endotheliitis markers and in vitro endothelial effects. A BMC Medicine 2024 study assessed 88 ICU survivors at 6 months post‑ICU discharge; patients with impaired gas exchange showed elevated plasma markers of endothelial inflammation (ICAM‑1, IL‑8, CCL‑2, ET‑1) and systemic inflammation (NLRP3 overexpression; IL‑6, sCD40‑L, CRP), with persistent IFN‑β and T cell activation markers. (alfaro2024endothelialdysfunctionand pages 1-2)
In vitro, post‑COVID patient plasma increased endothelial activation in HUVECs (e.g., “augmented ICAM‑1 expression,” increased active caspase‑1, increased ET‑1), and IFN‑β inhibition reduced ET‑1 release. (alfaro2024endothelialdysfunctionand pages 8-10)
Thrombotic endothelialitis biomarker panel. A 2024 Seminars in Thrombosis and Hemostasis study reports increased soluble concentrations of VWF, PF4, SAA, α‑2 antiplasmin (α‑2AP), E‑selectin, and PECAM‑1 in long COVID. The mean α‑2AP exceeded the upper reference limit, and the authors interpret microclotting plus these biomarkers as evidence that thrombotic endothelialitis is a key pathological process. (turner2024increasedlevelsof pages 1-2)
Microclots as partial explanation and heterogeneity. A review on microthrombosis emphasizes that microclots may contribute to PASC but cannot explain all symptoms, and anticoagulation/antiplatelet evidence is inconsistent, supporting symptom/biomarker-based stratification. (turner2024increasedlevelsof pages 1-2)
Muscle pathology and post-exertional malaise (PEM). A Nature Communications 2024 longitudinal case-control study induced PEM with maximal exercise and performed paired biopsies. Long COVID patients had reduced exercise capacity (lower V̇O2max/peak power) and lower peripheral O2 extraction by NIRS, alongside structural abnormalities and inflammation in muscle. (appelman2024muscleabnormalitiesworsen pages 3-4, appelman2024muscleabnormalitiesworsen pages 2-3)
Direct mitochondrial/metabolic findings in muscle. The study reports: - “Oxidative phosphorylation (OXPHOS) capacity was significantly lower in patients with long COVID … and remained lower one day after induction of post-exertional malaise.” (appelman2024muscleabnormalitiesworsen pages 5-6) - Muscle metabolomics showed key TCA metabolites (e.g., glutamate, FAD+, α‑ketoglutarate, citric acid) and a lower citric acid:lactate ratio in patients, consistent with reduced oxidative metabolism; venous blood showed higher glycolytic metabolites and lower pyruvate/TCA metabolites. (appelman2024muscleabnormalitiesworsen pages 3-4)
Amyloid-containing deposits in muscle. The same study reports “an increased accumulation of amyloid-containing deposits in skeletal muscle” in long COVID, higher at baseline and increasing after exercise; deposits were extracellular/adjacent to endothelium rather than within endothelial cells. (appelman2024muscleabnormalitiesworsen pages 6-7)
Below are key molecules supported by the evidence corpus, grouped by mechanism.
Viral entry/tropism / tissue injury - ACE2 (viral entry receptor; endothelial and GI expression; spike effects on ACE2). (wu2024damagetoendothelial pages 1-2, bohmwald2024pathophysiologicalimmunologicaland pages 12-12)
Cytokines/chemokines and immune signaling - IFNG (IFN‑γ) and type II IFN signaling endotype. (talla2023persistentserumprotein pages 6-7, talla2023persistentserumprotein pages 1-2) - TNF and canonical NF‑κB signaling enrichment. (talla2023persistentserumprotein pages 6-7, talla2023persistentserumprotein pages 1-2) - IL6, IL1B (inflammatory mediators linked to endotheliopathy/inflammation). (wu2024damagetoendothelial pages 1-2, talla2023persistentserumprotein pages 6-7) - CXCL9/CXCL10 (IP‑10)/CXCL11 (I‑TAC) in IFN‑γ endotype and JKMS cytokines. (talla2023persistentserumprotein pages 6-7, ra2024viralimmunologicand pages 5-6) - IL17A, IL2, VEGFA/VEGF, CCL5 (RANTES), CD40LG (sCD40L), GZMA elevated in PASC cohort. (ra2024viralimmunologicand pages 5-6, ra2024viralimmunologicand pages 1-2)
Innate sensing / type I IFN-associated proteins (proteomics) - DDX58 (RIG‑I), SAMD9L, LAMP3, MNDA in persistent type I IFN–associated signature. (talla2023persistentserumprotein pages 6-7)
Inflammasome / endothelial activation - NLRP3 (inflammasome activation; monocyte overexpression; endothelial transcript changes). (alfaro2024endothelialdysfunctionand pages 5-8, gusev2024exploringthepathophysiology pages 2-4) - IFI16 (endothelial inflammatory response marker in HUVEC model). (alfaro2024endothelialdysfunctionand pages 5-8) - ICAM1, PECAM1 (CD31), SELE (E‑selectin) endothelial activation markers. (wu2024damagetoendothelial pages 1-2, turner2024increasedlevelsof pages 1-2) - EDN1 (ET‑1) vasoconstrictor; elevated in severe post‑COVID with impaired gas exchange; IFN‑β linked in vitro. (alfaro2024endothelialdysfunctionand pages 1-2, alfaro2024endothelialdysfunctionand pages 8-10)
Coagulation/fibrinolysis and platelet activation - VWF, PF4, SERPINF2 (α‑2AP), SAA1/2 (serum amyloid A). (turner2024increasedlevelsof pages 1-2)
Evidence-supported metabolites altered in long COVID muscle/blood: - FAD+, α‑ketoglutarate, citric acid, lactate, glutamate, creatine, S‑adenosylmethionine (SAM). (appelman2024muscleabnormalitiesworsen pages 3-4)
Therapeutically relevant small molecules/drugs with mechanistic rationale: - Nirmatrelvir/ritonavir (Paxlovid) (antiviral; trials and observational signals discussed as modifying long COVID risk). (peluso2024mechanismsoflong pages 6-8) - Metformin (trial evidence for reduced later long COVID diagnoses is discussed in Cell 2024 review). (peluso2024mechanismsoflong pages 6-8)
The following GO-style process categories are supported by the evidence corpus:
Supported cellular component categories include: - Plasma/serum (antigenemia; cytokines; proteomics signatures). (ra2024viralimmunologicand pages 2-4, talla2023persistentserumprotein pages 10-11) - Extracellular vesicles (review-level evidence of viral/mitochondrial proteins in exosomes in long COVID synthesis). (peluso2024mechanismsoflong pages 38-40) - Endothelial glycocalyx (shedding; barrier dysfunction). (wu2024damagetoendothelial pages 1-2) - Extracellular matrix (muscle nucleocapsid localization and amyloid deposits were extracellular/adjacent to endothelium). (appelman2024muscleabnormalitiesworsen pages 5-6, appelman2024muscleabnormalitiesworsen pages 6-7) - Mitochondrion (OXPHOS capacity; SDH activity). (appelman2024muscleabnormalitiesworsen pages 5-6) - Inflammasome complex (NLRP3-associated) (monocyte MFI readouts; endothelial pyroptosis markers). (alfaro2024endothelialdysfunctionand pages 5-8) - Blood–brain barrier and other endothelial barriers (review synthesis of multi-organ endothelial barriers: blood–air, blood–brain, glomerular filtration, intestinal–blood). (wu2024damagetoendothelial pages 1-2)
A synthesis consistent across recent authoritative sources supports the following progression:
Below are key phenotypes supported by the evidence corpus and their mechanistic anchors.
Trials retrieved via registry search reflect active translation of mechanistic hypotheses into therapeutics: - Nirmatrelvir/ritonavir (Paxlovid) for prevention or treatment (e.g., decentralized phase 2 long COVID study; platform protocols). Examples include NCT05668091, NCT05576662, NCT05965726, and a large prevention trial NCT05852873. (peluso2024mechanismsoflong pages 6-8) - Immunoadsorption (autoantibody/immune complex targeting): sham-controlled and other designs (e.g., NCT05954325, NCT05841498, NCT07316127). (peluso2024mechanismsoflong pages 6-8) - Ivabradine for POTS cohort: NCT05481177 reflects autonomic phenotype targeting. (peluso2024mechanismsoflong pages 6-8)
PMIDs were not consistently present in extracted text; DOIs/URLs are provided for traceability.
References
(untersmayr2024immunemechanismsunderpinning pages 2-2): Eva Untersmayr, Carina Venter, Peter Smith, Johanna Rohrhofer, Cebile Ndwandwe, Jurgen Schwarze, Emer Shannon, Milena Sokolowska, Corinna Sadlier, and Liam O’Mahony. Immune mechanisms underpinning long covid: collegium internationale allergologicum update 2024. International Archives of Allergy and Immunology, 185:489-502, Jan 2024. URL: https://doi.org/10.1159/000535736, doi:10.1159/000535736. This article has 17 citations and is from a peer-reviewed journal.
(untersmayr2024immunemechanismsunderpinning pages 1-2): Eva Untersmayr, Carina Venter, Peter Smith, Johanna Rohrhofer, Cebile Ndwandwe, Jurgen Schwarze, Emer Shannon, Milena Sokolowska, Corinna Sadlier, and Liam O’Mahony. Immune mechanisms underpinning long covid: collegium internationale allergologicum update 2024. International Archives of Allergy and Immunology, 185:489-502, Jan 2024. URL: https://doi.org/10.1159/000535736, doi:10.1159/000535736. This article has 17 citations and is from a peer-reviewed journal.
(talla2023persistentserumprotein pages 6-7): Aarthi Talla, Suhas V. Vasaikar, Gregory Lee Szeto, Maria P. Lemos, Julie L. Czartoski, Hugh MacMillan, Zoe Moodie, Kristen W. Cohen, Lamar B. Fleming, Zachary Thomson, Lauren Okada, Lynne A. Becker, Ernest M. Coffey, Stephen C. De Rosa, Evan W. Newell, Peter J. Skene, Xiaojun Li, Thomas F. Bumol, M. Juliana McElrath, and Troy R. Torgerson. Persistent serum protein signatures define an inflammatory subcategory of long covid. Nature Communications, Jun 2023. URL: https://doi.org/10.1038/s41467-023-38682-4, doi:10.1038/s41467-023-38682-4. This article has 115 citations and is from a highest quality peer-reviewed journal.
(talla2023persistentserumprotein pages 1-2): Aarthi Talla, Suhas V. Vasaikar, Gregory Lee Szeto, Maria P. Lemos, Julie L. Czartoski, Hugh MacMillan, Zoe Moodie, Kristen W. Cohen, Lamar B. Fleming, Zachary Thomson, Lauren Okada, Lynne A. Becker, Ernest M. Coffey, Stephen C. De Rosa, Evan W. Newell, Peter J. Skene, Xiaojun Li, Thomas F. Bumol, M. Juliana McElrath, and Troy R. Torgerson. Persistent serum protein signatures define an inflammatory subcategory of long covid. Nature Communications, Jun 2023. URL: https://doi.org/10.1038/s41467-023-38682-4, doi:10.1038/s41467-023-38682-4. This article has 115 citations and is from a highest quality peer-reviewed journal.
(proal2023sarscov2reservoirin pages 4-6): Amy D. Proal, Michael B. VanElzakker, Soo Aleman, Katie Bach, Brittany P. Boribong, Marcus Buggert, Sara Cherry, Daniel S. Chertow, Helen E. Davies, Christopher L. Dupont, Steven G. Deeks, William Eimer, E. Wesley Ely, Alessio Fasano, Marcelo Freire, Linda N. Geng, Diane E. Griffin, Timothy J. Henrich, Akiko Iwasaki, David Izquierdo-Garcia, Michela Locci, Saurabh Mehandru, Mark M. Painter, Michael J. Peluso, Etheresia Pretorius, David A. Price, David Putrino, Richard H. Scheuermann, Gene S. Tan, Rudolph E. Tanzi, Henry F. VanBrocklin, Lael M. Yonker, and E. John Wherry. Sars-cov-2 reservoir in post-acute sequelae of covid-19 (pasc). Nature Immunology, 24:1616-1627, Sep 2023. URL: https://doi.org/10.1038/s41590-023-01601-2, doi:10.1038/s41590-023-01601-2. This article has 323 citations and is from a highest quality peer-reviewed journal.
(gusev2024exploringthepathophysiology pages 2-4): Evgenii Gusev and Alexey Sarapultsev. Exploring the pathophysiology of long covid: the central role of low-grade inflammation and multisystem involvement. International Journal of Molecular Sciences, 25:6389, Jun 2024. URL: https://doi.org/10.3390/ijms25126389, doi:10.3390/ijms25126389. This article has 37 citations.
(ra2024viralimmunologicand pages 2-4): Sang Hyun Ra, Euijin Chang, Ji-Soo Kwon, Ji Yeun Kim, JuYeon Son, Woori Kim, Choi Young Jang, Hyeon Mu Jang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Keun Hwa Lee, and Sung-Han Kim. Viral, immunologic, and laboratory parameters in patients with and without post-acute sequelae of sars-cov-2 infection (pasc). Journal of Korean Medical Science, Jul 2024. URL: https://doi.org/10.3346/jkms.2024.39.e237, doi:10.3346/jkms.2024.39.e237. This article has 3 citations and is from a peer-reviewed journal.
(peluso2024mechanismsoflong pages 6-8): Michael J. Peluso and Steven G. Deeks. Mechanisms of long covid and the path toward therapeutics. Oct 2024. URL: https://doi.org/10.1016/j.cell.2024.07.054, doi:10.1016/j.cell.2024.07.054. This article has 249 citations and is from a highest quality peer-reviewed journal.
(talla2023persistentserumprotein pages 10-11): Aarthi Talla, Suhas V. Vasaikar, Gregory Lee Szeto, Maria P. Lemos, Julie L. Czartoski, Hugh MacMillan, Zoe Moodie, Kristen W. Cohen, Lamar B. Fleming, Zachary Thomson, Lauren Okada, Lynne A. Becker, Ernest M. Coffey, Stephen C. De Rosa, Evan W. Newell, Peter J. Skene, Xiaojun Li, Thomas F. Bumol, M. Juliana McElrath, and Troy R. Torgerson. Persistent serum protein signatures define an inflammatory subcategory of long covid. Nature Communications, Jun 2023. URL: https://doi.org/10.1038/s41467-023-38682-4, doi:10.1038/s41467-023-38682-4. This article has 115 citations and is from a highest quality peer-reviewed journal.
(ra2024viralimmunologicand pages 5-6): Sang Hyun Ra, Euijin Chang, Ji-Soo Kwon, Ji Yeun Kim, JuYeon Son, Woori Kim, Choi Young Jang, Hyeon Mu Jang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Keun Hwa Lee, and Sung-Han Kim. Viral, immunologic, and laboratory parameters in patients with and without post-acute sequelae of sars-cov-2 infection (pasc). Journal of Korean Medical Science, Jul 2024. URL: https://doi.org/10.3346/jkms.2024.39.e237, doi:10.3346/jkms.2024.39.e237. This article has 3 citations and is from a peer-reviewed journal.
(ra2024viralimmunologicand pages 1-2): Sang Hyun Ra, Euijin Chang, Ji-Soo Kwon, Ji Yeun Kim, JuYeon Son, Woori Kim, Choi Young Jang, Hyeon Mu Jang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Keun Hwa Lee, and Sung-Han Kim. Viral, immunologic, and laboratory parameters in patients with and without post-acute sequelae of sars-cov-2 infection (pasc). Journal of Korean Medical Science, Jul 2024. URL: https://doi.org/10.3346/jkms.2024.39.e237, doi:10.3346/jkms.2024.39.e237. This article has 3 citations and is from a peer-reviewed journal.
(wu2024damagetoendothelial pages 1-2): Xiaoming Wu, Mengqi Xiang, Haijiao Jing, Chengyue Wang, Valerie A. Novakovic, and Jialan Shi. Damage to endothelial barriers and its contribution to long covid. Angiogenesis, 27:1-18, Apr 2024. URL: https://doi.org/10.1007/s10456-023-09878-5, doi:10.1007/s10456-023-09878-5. This article has 102 citations and is from a domain leading peer-reviewed journal.
(alfaro2024endothelialdysfunctionand pages 1-2): Enrique Alfaro, Elena Díaz-García, Sara García-Tovar, Raúl Galera, Raquel Casitas, María Torres-Vargas, Cristina López-Fernández, José M. Añón, Francisco García-Río, and Carolina Cubillos-Zapata. Endothelial dysfunction and persistent inflammation in severe post-covid-19 patients: implications for gas exchange. BMC Medicine, Jun 2024. URL: https://doi.org/10.1186/s12916-024-03461-5, doi:10.1186/s12916-024-03461-5. This article has 29 citations and is from a domain leading peer-reviewed journal.
(alfaro2024endothelialdysfunctionand pages 8-10): Enrique Alfaro, Elena Díaz-García, Sara García-Tovar, Raúl Galera, Raquel Casitas, María Torres-Vargas, Cristina López-Fernández, José M. Añón, Francisco García-Río, and Carolina Cubillos-Zapata. Endothelial dysfunction and persistent inflammation in severe post-covid-19 patients: implications for gas exchange. BMC Medicine, Jun 2024. URL: https://doi.org/10.1186/s12916-024-03461-5, doi:10.1186/s12916-024-03461-5. This article has 29 citations and is from a domain leading peer-reviewed journal.
(turner2024increasedlevelsof pages 1-2): BSc Simone Turner, BSc Caitlin A. Naidoo, BSc Thomas J. Usher, MD Arneaux Kruger, PhD Chantelle Venter, MD Gert J. Laubscher, Frcp M Asad Khan, PhD Douglas B. Kell, and PhD Etheresia Pretorius. Increased levels of inflammatory and endothelial biomarkers in blood of long covid patients point to thrombotic endothelialitis. Seminars in Thrombosis and Hemostasis, 50:288-294, May 2024. URL: https://doi.org/10.1055/s-0043-1769014, doi:10.1055/s-0043-1769014. This article has 50 citations and is from a peer-reviewed journal.
(appelman2024muscleabnormalitiesworsen pages 3-4): Brent Appelman, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, Frank W. Bloemers, Michel van Weeghel, Bauke V. Schomakers, Pedro Coelho, Jelle J. Posthuma, Eleonora Aronica, W. Joost Wiersinga, Michèle van Vugt, and Rob C. I. Wüst. Muscle abnormalities worsen after post-exertional malaise in long covid. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44432-3, doi:10.1038/s41467-023-44432-3. This article has 346 citations and is from a highest quality peer-reviewed journal.
(appelman2024muscleabnormalitiesworsen pages 2-3): Brent Appelman, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, Frank W. Bloemers, Michel van Weeghel, Bauke V. Schomakers, Pedro Coelho, Jelle J. Posthuma, Eleonora Aronica, W. Joost Wiersinga, Michèle van Vugt, and Rob C. I. Wüst. Muscle abnormalities worsen after post-exertional malaise in long covid. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44432-3, doi:10.1038/s41467-023-44432-3. This article has 346 citations and is from a highest quality peer-reviewed journal.
(appelman2024muscleabnormalitiesworsen pages 5-6): Brent Appelman, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, Frank W. Bloemers, Michel van Weeghel, Bauke V. Schomakers, Pedro Coelho, Jelle J. Posthuma, Eleonora Aronica, W. Joost Wiersinga, Michèle van Vugt, and Rob C. I. Wüst. Muscle abnormalities worsen after post-exertional malaise in long covid. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44432-3, doi:10.1038/s41467-023-44432-3. This article has 346 citations and is from a highest quality peer-reviewed journal.
(appelman2024muscleabnormalitiesworsen pages 6-7): Brent Appelman, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, Frank W. Bloemers, Michel van Weeghel, Bauke V. Schomakers, Pedro Coelho, Jelle J. Posthuma, Eleonora Aronica, W. Joost Wiersinga, Michèle van Vugt, and Rob C. I. Wüst. Muscle abnormalities worsen after post-exertional malaise in long covid. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44432-3, doi:10.1038/s41467-023-44432-3. This article has 346 citations and is from a highest quality peer-reviewed journal.
(bohmwald2024pathophysiologicalimmunologicaland pages 12-12): Karen Bohmwald, Benjamín Diethelm-Varela, Linmar Rodríguez-Guilarte, Thomas Rivera, Claudia A. Riedel, Pablo A. González, and Alexis M. Kalergis. Pathophysiological, immunological, and inflammatory features of long covid. Frontiers in Immunology, Feb 2024. URL: https://doi.org/10.3389/fimmu.2024.1341600, doi:10.3389/fimmu.2024.1341600. This article has 72 citations and is from a peer-reviewed journal.
(alfaro2024endothelialdysfunctionand pages 5-8): Enrique Alfaro, Elena Díaz-García, Sara García-Tovar, Raúl Galera, Raquel Casitas, María Torres-Vargas, Cristina López-Fernández, José M. Añón, Francisco García-Río, and Carolina Cubillos-Zapata. Endothelial dysfunction and persistent inflammation in severe post-covid-19 patients: implications for gas exchange. BMC Medicine, Jun 2024. URL: https://doi.org/10.1186/s12916-024-03461-5, doi:10.1186/s12916-024-03461-5. This article has 29 citations and is from a domain leading peer-reviewed journal.
(proal2023sarscov2reservoirin pages 8-10): Amy D. Proal, Michael B. VanElzakker, Soo Aleman, Katie Bach, Brittany P. Boribong, Marcus Buggert, Sara Cherry, Daniel S. Chertow, Helen E. Davies, Christopher L. Dupont, Steven G. Deeks, William Eimer, E. Wesley Ely, Alessio Fasano, Marcelo Freire, Linda N. Geng, Diane E. Griffin, Timothy J. Henrich, Akiko Iwasaki, David Izquierdo-Garcia, Michela Locci, Saurabh Mehandru, Mark M. Painter, Michael J. Peluso, Etheresia Pretorius, David A. Price, David Putrino, Richard H. Scheuermann, Gene S. Tan, Rudolph E. Tanzi, Henry F. VanBrocklin, Lael M. Yonker, and E. John Wherry. Sars-cov-2 reservoir in post-acute sequelae of covid-19 (pasc). Nature Immunology, 24:1616-1627, Sep 2023. URL: https://doi.org/10.1038/s41590-023-01601-2, doi:10.1038/s41590-023-01601-2. This article has 323 citations and is from a highest quality peer-reviewed journal.
(appelman2024muscleabnormalitiesworsen pages 8-9): Brent Appelman, Braeden T. Charlton, Richie P. Goulding, Tom J. Kerkhoff, Ellen A. Breedveld, Wendy Noort, Carla Offringa, Frank W. Bloemers, Michel van Weeghel, Bauke V. Schomakers, Pedro Coelho, Jelle J. Posthuma, Eleonora Aronica, W. Joost Wiersinga, Michèle van Vugt, and Rob C. I. Wüst. Muscle abnormalities worsen after post-exertional malaise in long covid. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44432-3, doi:10.1038/s41467-023-44432-3. This article has 346 citations and is from a highest quality peer-reviewed journal.
(talla2023persistentserumprotein pages 11-12): Aarthi Talla, Suhas V. Vasaikar, Gregory Lee Szeto, Maria P. Lemos, Julie L. Czartoski, Hugh MacMillan, Zoe Moodie, Kristen W. Cohen, Lamar B. Fleming, Zachary Thomson, Lauren Okada, Lynne A. Becker, Ernest M. Coffey, Stephen C. De Rosa, Evan W. Newell, Peter J. Skene, Xiaojun Li, Thomas F. Bumol, M. Juliana McElrath, and Troy R. Torgerson. Persistent serum protein signatures define an inflammatory subcategory of long covid. Nature Communications, Jun 2023. URL: https://doi.org/10.1038/s41467-023-38682-4, doi:10.1038/s41467-023-38682-4. This article has 115 citations and is from a highest quality peer-reviewed journal.
(proal2023sarscov2reservoirin pages 10-12): Amy D. Proal, Michael B. VanElzakker, Soo Aleman, Katie Bach, Brittany P. Boribong, Marcus Buggert, Sara Cherry, Daniel S. Chertow, Helen E. Davies, Christopher L. Dupont, Steven G. Deeks, William Eimer, E. Wesley Ely, Alessio Fasano, Marcelo Freire, Linda N. Geng, Diane E. Griffin, Timothy J. Henrich, Akiko Iwasaki, David Izquierdo-Garcia, Michela Locci, Saurabh Mehandru, Mark M. Painter, Michael J. Peluso, Etheresia Pretorius, David A. Price, David Putrino, Richard H. Scheuermann, Gene S. Tan, Rudolph E. Tanzi, Henry F. VanBrocklin, Lael M. Yonker, and E. John Wherry. Sars-cov-2 reservoir in post-acute sequelae of covid-19 (pasc). Nature Immunology, 24:1616-1627, Sep 2023. URL: https://doi.org/10.1038/s41590-023-01601-2, doi:10.1038/s41590-023-01601-2. This article has 323 citations and is from a highest quality peer-reviewed journal.
(peluso2024mechanismsoflong pages 38-40): Michael J. Peluso and Steven G. Deeks. Mechanisms of long covid and the path toward therapeutics. Oct 2024. URL: https://doi.org/10.1016/j.cell.2024.07.054, doi:10.1016/j.cell.2024.07.054. This article has 249 citations and is from a highest quality peer-reviewed journal.
(durstenfeld2024longcovidand pages 16-17): Matthew S. Durstenfeld, Shannon Weiman, Michael Holtzman, Catherine Blish, Resia Pretorius, and Steven G. Deeks. Long covid and post-acute sequelae of sars-cov-2 pathogenesis and treatment: a keystone symposia report. Annals of the New York Academy of Sciences, 1535:31-41, Apr 2024. URL: https://doi.org/10.1111/nyas.15132, doi:10.1111/nyas.15132. This article has 7 citations and is from a peer-reviewed journal.
name: Long COVID
synonyms:
- Post-COVID-19 condition
- Post-acute sequelae of SARS-CoV-2 infection
- PASC
creation_date: '2026-01-12T22:00:21Z'
updated_date: '2026-03-04T22:20:00Z'
category: Complex
description: >
Long COVID, formally designated as Post-acute Sequelae of SARS-CoV-2 (PASC),
is a complex, multisystem condition characterized by persistent symptoms following
resolution of acute SARS-CoV-2 infection. The condition can develop following both
mild and severe acute illness and affects an estimated 65 million individuals worldwide.
disease_term:
preferred_term: Long COVID
term:
id: MONDO:0100233
label: long COVID-19
mappings:
mondo_mappings:
- term:
id: MONDO:0100233
label: long COVID-19
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: Primary MONDO disease identifier for this Long COVID entry.
parents:
- Post-viral syndrome
- COVID-19 complications
has_subtypes:
- name: Pain-dominant long COVID phenotype
description: >
Symptom-cluster phenotype enriched for joint pain, myalgia, and headache.
classification: symptom_cluster
evidence:
- reference: PMID:35265728
reference_title: "Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cluster 1 had predominantly pain symptoms with a higher proportion of joint pain, myalgia, and headache;"
explanation: Cluster analysis identifies a pain-predominant long-COVID subtype.
- name: Cardiopulmonary-dominant long COVID phenotype
description: >
Symptom-cluster phenotype enriched for chest pain, shortness of breath, and palpitations.
classification: symptom_cluster
evidence:
- reference: PMID:35265728
reference_title: "Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "cluster 2 had a preponderance of cardiovascular symptoms with prominent chest pain, shortness of breath, and palpitations;"
explanation: Cluster analysis identifies a cardiopulmonary symptom-dominant subtype.
- name: Oligosymptomatic long COVID phenotype
description: >
Symptom-cluster phenotype with lower symptom burden than pain- and cardiopulmonary-dominant groups.
classification: symptom_cluster
evidence:
- reference: PMID:35265728
reference_title: "Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "cluster 3 had significantly fewer symptoms than the other clusters"
explanation: Cluster analysis identifies a lower-symptom-burden subtype.
infectious_agent:
- name: SARS-CoV-2
infectious_agent_term:
preferred_term: SARS-CoV-2
term:
id: NCBITaxon:2697049
label: Severe acute respiratory syndrome coronavirus 2
description: Causal antecedent infection for post-COVID-19 condition.
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
explanation: Establishes prior SARS-CoV-2 infection as a defining prerequisite for Long COVID.
prevalence:
- population: COVID-19 survivors (mixed hospitalization status)
percentage: "~45% with at least one unresolved symptom at mean follow-up of 126 days"
evidence:
- reference: PMID:36474804
reference_title: "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "On average, at least 45% of COVID-19 survivors, regardless of hospitalisation status, went on to experience at least one unresolved symptom (mean follow-up 126 days)."
explanation: Provides pooled prevalence of unresolved post-COVID symptoms across global cohorts.
- population: Adults with prior SARS-CoV-2 infection (Victoria, Australia)
percentage: "14.2% clinical long COVID"
evidence:
- reference: PMID:39489523
reference_title: "Persistent symptoms after COVID-19: an Australian stratified random health survey on long COVID."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A total of 1656 respondents (14.2%; 95% CI, 13.4-15.0%) were classified as having clinical long COVID using the criteria of at least one persistent new symptom and less than 80% recovery three months after the infection."
explanation: Reports cohort-level frequency of clinically defined long COVID in a large stratified random survey.
epidemiology:
- name: Persistent symptom burden after COVID-19
description: Persistent symptoms remain common in both hospitalized and non-hospitalized survivors.
minimum_value: 45
unit: percentage
factors:
- Follow-up duration after acute infection
- Case mix of hospitalized and non-hospitalized cohorts
evidence:
- reference: PMID:36474804
reference_title: "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our work shows that 45% of COVID-19 survivors, regardless of hospitalisation status, were experiencing a range of unresolved symptoms at ∼ 4 months."
explanation: Quantifies substantial ongoing symptom burden during post-acute follow-up.
- name: Risk factors for clinical long COVID
description: Demographic and acute-illness characteristics influence long-COVID risk.
factors:
- female sex
- age
- severe acute illness
- chronic illness/comorbidity burden
- higher BMI
evidence:
- reference: PMID:37866679
reference_title: "Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Factors frequently associated with a higher prevalence of persistent symptoms included female gender, advanced age, severe illness during the acute phase of COVID-19, multiple comorbidities, an extended duration of hospital stay, and a high body mass index."
explanation: Systematic-review evidence identifies reproducible risk factors associated with post-COVID persistent symptoms.
- reference: PMID:39489523
reference_title: "Persistent symptoms after COVID-19: an Australian stratified random health survey on long COVID."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The risk factors for clinical long COVID were female sex, age 40-49 years, infection severity, chronic illness, and past anxiety or depression."
explanation: Population survey confirms major risk factors for clinically defined long COVID.
progression:
- phase: Post-acute case-definition window
notes: Symptoms usually emerge or persist around three months from acute infection and continue for at least two months.
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
explanation: Defines the canonical temporal window used for post-acute progression of Long COVID.
- phase: Fluctuating or relapsing course
notes: Symptom burden may wax and wane over time rather than following a monotonic recovery trajectory.
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Symptoms might also fluctuate or relapse over time."
explanation: Directly supports relapsing-remitting progression patterns.
- phase: Persistent unresolved symptoms at medium-term follow-up
notes: A substantial fraction of survivors continue to report unresolved symptoms around four months after acute infection.
evidence:
- reference: PMID:36474804
reference_title: "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our work shows that 45% of COVID-19 survivors, regardless of hospitalisation status, were experiencing a range of unresolved symptoms at ∼ 4 months."
explanation: Supports sustained medium-term disease burden in mixed populations.
stages:
- name: Early post-acute persistent symptom stage
description: Ongoing symptoms beyond four weeks after acute infection.
evidence:
- reference: PMID:35265728
reference_title: "Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "individuals with a confirmed diagnosis of COVID-19 and persistent symptoms >4 weeks from onset of acute symptoms."
explanation: Defines an early persistent-symptom stage soon after the acute phase.
- name: Established WHO post-COVID-19 condition stage
description: Symptoms usually present around three months from onset and persist at least two months without alternative explanation.
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
explanation: Anchors the established condition stage to WHO consensus timing criteria.
- name: Medium-term unresolved symptom stage
description: Significant proportion of survivors continue to report unresolved symptoms around four months.
evidence:
- reference: PMID:36474804
reference_title: "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our work shows that 45% of COVID-19 survivors, regardless of hospitalisation status, were experiencing a range of unresolved symptoms at ∼ 4 months."
explanation: Supports persistent disease burden into medium-term follow-up.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_persistence_immune_model
hypothesis_label: Canonical Viral Persistence-Immune Dysregulation Model
status: CANONICAL
description: >
Persistent viral RNA/antigen reservoirs sustain immune activation and downstream
multisystem dysfunction, providing the default explanatory framework for Long COVID.
applies_to_subtypes:
- Pain-dominant long COVID phenotype
- Cardiopulmonary-dominant long COVID phenotype
evidence:
- reference: PMID:37140960
reference_title: "Viral persistence, reactivation, and mechanisms of long COVID."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear."
explanation: Supports reservoir persistence linked to pathogenic immune responses.
- hypothesis_group_id: vascular_microclot_model
hypothesis_label: Endothelial-Microclot Perfusion Model
status: ALTERNATIVE
description: >
Fibrin amyloid microclots impair capillary flow and oxygen exchange, driving
fatigue, dyspnea, and energy deficits in a vascular-predominant subtype.
applies_to_subtypes:
- Cardiopulmonary-dominant long COVID phenotype
evidence:
- reference: PMID:35195253
reference_title: "A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the ability of these fibrin amyloid microclots (fibrinaloids) to block up capillaries, and thus to limit the passage of red blood cells and hence O2 exchange, can actually underpin the majority of these symptoms"
explanation: Supports a perfusion-limitation mechanism that can coexist with immune-driven models.
- hypothesis_group_id: serotonin_vagal_model
hypothesis_label: Serotonin-Vagus-Hippocampal Signaling Model
status: EMERGING
description: >
Interferon-linked serotonin depletion impairs vagal signaling and hippocampal
responses, contributing to cognitive and autonomic symptoms.
applies_to_subtypes:
- Pain-dominant long COVID phenotype
- Oligosymptomatic long COVID phenotype
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory."
explanation: Supports an emerging gut-immune-neuro axis in Long COVID.
- hypothesis_group_id: mastcell_neuroimmune_model
hypothesis_label: Mast Cell-BBB Neuroinflammation Model
status: EMERGING
description: >
Mast-cell activation may compromise BBB integrity and promote neuroinflammation,
amplifying cognitive and neuropsychiatric manifestations.
applies_to_subtypes:
- Pain-dominant long COVID phenotype
- Cardiopulmonary-dominant long COVID phenotype
evidence:
- reference: PMID:38638822
reference_title: "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "These findings reveal a cellular mechanism of SARS-CoV-2-induced neuroinflammation."
explanation: Provides mechanistic cellular support for mast-cell-associated neuroinflammatory pathways.
diagnosis:
- name: WHO post-COVID-19 clinical case definition
presence: History of probable or confirmed SARS-CoV-2 infection, symptoms usually beginning by about 3 months, lasting at least 2 months, and not explained by an alternative diagnosis.
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
explanation: Provides consensus diagnostic framework for adult post-COVID-19 condition.
- name: Functional-impact symptom profile
presence: Persistent fatigue, dyspnea, and/or cognitive dysfunction with daily-function impact support clinical diagnosis.
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Common symptoms include, but are not limited to, fatigue, shortness of breath, and cognitive dysfunction, and generally have an impact on everyday functioning."
explanation: Defines core symptom constellation and functional impact used in diagnosis.
environmental:
- name: Infection during ancestral-strain dominance
presence: Associated with higher risk
effect: Increased risk of clinical long COVID compared with later Delta/Omicron-dominant periods.
evidence:
- reference: PMID:39489523
reference_title: "Persistent symptoms after COVID-19: an Australian stratified random health survey on long COVID."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Factors associated with a decreased risk of having clinical long COVID included infection when the Omicron strain was dominant and infection when the Delta strain was dominant, as compared with when the ancestral strain of the virus was dominant."
explanation: Indicates infection-context effects by circulating variant period on long-COVID risk.
definitions:
- name: WHO clinical case definition for post-COVID-19 condition
definition_type: CASE_DEFINITION
description: >
Consensus case definition produced through a WHO-led Delphi process for adult
post-COVID-19 condition (Long COVID), anchored to prior SARS-CoV-2 infection,
minimum symptom duration, and exclusion of alternative diagnoses.
scope: Adults
notes: WHO notes that a separate pediatric definition might be applicable for children.
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
explanation: Provides the core timing and exclusion-based WHO case-definition criteria.
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Common symptoms include, but are not limited to, fatigue, shortness of breath, and cognitive dysfunction, and generally have an impact on everyday functioning."
explanation: Supports inclusion of key symptom domains and functional impact in the case definition.
modeling_considerations:
- name: Phenotype harmonization across cohorts
description: >
Long COVID analyses should standardize symptom terminology (for example via HPO)
because cross-study synonym variability and inconsistent ascertainment reduce
comparability and pooling.
evidence:
- reference: PMID:34839263
reference_title: "Characterizing Long COVID: Deep Phenotype of a Complex Condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Long COVID clinical manifestations are not assessed consistently across studies, and most manifestations have been reported with a wide range of synonyms by different authors."
explanation: Directly identifies ascertainment and terminology heterogeneity that modeling pipelines must normalize.
- reference: PMID:34839263
reference_title: "Characterizing Long COVID: Deep Phenotype of a Complex Condition."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "If researchers, clinicians, and patients share a common language, then studies can be compared/pooled more effectively."
explanation: Supports ontology-based harmonization as a practical prerequisite for pooled modeling.
- name: Stratified risk and trajectory modeling
description: >
Models should include stratification by acute severity, demographics,
comorbidities, and follow-up window, because these factors materially influence
long-COVID prevalence and symptom trajectories.
evidence:
- reference: PMID:37866679
reference_title: "Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Factors frequently associated with a higher prevalence of persistent symptoms included female gender, advanced age, severe illness during the acute phase of COVID-19, multiple comorbidities, an extended duration of hospital stay, and a high body mass index."
explanation: Identifies major covariates that should be explicit model features for risk estimation.
- reference: PMID:36474804
reference_title: "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Current understanding is limited by heterogeneous study design, follow-up durations, and measurement methods."
explanation: Emphasizes that trajectory models must account for follow-up and design heterogeneity.
references:
- reference: PMID:34951953
title: A clinical case definition of post-COVID-19 condition by a Delphi consensus.
findings:
- statement: WHO Delphi consensus defines adult post-COVID-19 condition using timing, symptom persistence, and exclusion criteria.
supporting_text: "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
evidence:
- reference: PMID:34951953
reference_title: "A clinical case definition of post-COVID-19 condition by a Delphi consensus."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
explanation: Captures the consensus WHO definition elements used in this page.
- reference: PMID:36474804
title: "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis."
findings:
- statement: Persistent symptoms affect a large fraction of survivors at medium-term follow-up.
supporting_text: "On average, at least 45% of COVID-19 survivors, regardless of hospitalisation status, went on to experience at least one unresolved symptom (mean follow-up 126 days)."
evidence:
- reference: PMID:36474804
reference_title: "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "On average, at least 45% of COVID-19 survivors, regardless of hospitalisation status, went on to experience at least one unresolved symptom (mean follow-up 126 days)."
explanation: Supports high unresolved-symptom prevalence across hospitalization strata.
- reference: PMID:37140960
title: "Viral persistence, reactivation, and mechanisms of long COVID."
findings:
- statement: Viral RNA or antigen persistence is documented and may contribute to pathogenic immune responses.
supporting_text: "Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear."
evidence:
- reference: PMID:37140960
reference_title: "Viral persistence, reactivation, and mechanisms of long COVID."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear."
explanation: Supports a persistence-driven mechanistic axis in Long COVID.
- reference: PMID:37848036
title: Serotonin reduction in post-acute sequelae of viral infection.
findings:
- statement: Serotonin depletion in PASC is linked to reduced tryptophan absorption, platelet effects, and increased MAO turnover.
supporting_text: "Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover."
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover."
explanation: Supports the serotonin-depletion mechanistic module in this disease model.
pathophysiology:
- name: Viral Persistence
description: >
SARS-CoV-2 viral reservoirs may persist in tissues including gut, brain,
and other organs for months after acute infection. The gastrointestinal tract
has emerged as a particularly significant reservoir site, with viral RNA detected
in approximately 30% of intestinal specimens from Long COVID patients.
cell_types:
- preferred_term: intestinal epithelial cell
term:
id: CL:0002563
label: intestinal epithelial cell
- preferred_term: CD8-positive T cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
evidence:
- reference: PMID:37140960
reference_title: "Viral persistence, reactivation, and mechanisms of long COVID."
supports: SUPPORT
snippet: "Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear."
explanation: Links Long COVID to persistence of SARS-CoV-2 RNA or antigen in tissues and resulting immune responses.
downstream:
- target: Systemic Immune Activation
description: Persistent viral antigens drive chronic immune activation and cytokine perturbations.
evidence:
- reference: PMID:37140960
reference_title: "Viral persistence, reactivation, and mechanisms of long COVID."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear."
explanation: Persistent tissue viral RNA/antigen supports continued immune stimulation in Long COVID.
- target: T Cell Exhaustion and Tissue Trafficking
description: Sustained antigen exposure from viral reservoirs leads to CD8+ T cell exhaustion and CD4+ tissue trafficking.
evidence:
- reference: PMID:37140960
reference_title: "Viral persistence, reactivation, and mechanisms of long COVID."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear."
explanation: Ongoing antigen exposure from reservoirs provides a mechanistic basis for chronic T cell activation/exhaustion states.
- target: Serotonin Depletion Mechanisms
description: Viral persistence and type I interferon-driven inflammation reduce serotonin through diminished tryptophan absorption, platelet hyperactivation, and enhanced MAO turnover.
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover."
explanation: Directly links persistent viral/inflammatory signaling to serotonin depletion pathways.
- target: Mast Cell Activation
description: Persistent viral antigens trigger mast cell degranulation and release of pro-inflammatory mediators.
evidence:
- reference: PMID:35938771
reference_title: "Mast cell activation syndrome and the link with long COVID."
supports: SUPPORT
evidence_source: OTHER
snippet: "COVID-19 infection could lead to exaggeration of existing undiagnosed mast cell activation syndrome, or could activate normal mast cells owing to the persistence of viral particles."
explanation: Directly links persistent viral particles to activation of normal mast cells.
- name: Systemic Immune Activation
description: >
Long COVID patients show ongoing systemic inflammation with altered T cell
subset distributions and cytokine perturbations, indicating chronic immune
activation and dysregulated signaling.
cell_types:
- preferred_term: CD4-positive T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: CD8-positive T cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
- preferred_term: JAK-STAT signaling
term:
id: GO:0007259
label: cell surface receptor signaling pathway via JAK-STAT
evidence:
- reference: PMID:38212464
reference_title: "Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2."
supports: SUPPORT
snippet: "LC individuals exhibited systemic inflammation and immune dysregulation. This was evidenced by global differences in T cell subset distribution implying ongoing immune responses, as well as by sex-specific perturbations in cytolytic subsets."
explanation: Demonstrates persistent systemic inflammation and altered immune signaling in Long COVID.
- reference: PMID:37748514
reference_title: "Distinguishing features of long COVID identified through immune profiling."
supports: SUPPORT
snippet: "Marked differences were noted in circulating myeloid and lymphocyte populations relative to the matched controls, as well as evidence of exaggerated humoral responses directed against SARS-CoV-2 among participants with long COVID."
explanation: Immune profiling shows broad myeloid/lymphocyte shifts and heightened humoral responses in Long COVID.
downstream:
- target: Neuroinflammation
description: Systemic inflammatory cytokines penetrate the blood-brain barrier and activate microglia.
evidence:
- reference: PMID:38212464
reference_title: "Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "LC individuals exhibited systemic inflammation and immune dysregulation. This was evidenced by global differences in T cell subset distribution implying ongoing immune responses, as well as by sex-specific perturbations in cytolytic subsets."
explanation: Supports persistent systemic inflammation in Long COVID, which plausibly drives downstream neuroinflammatory responses.
- target: Impaired Mitochondrial Energy Production
description: Chronic immune activation disrupts mitochondrial function and oxidative phosphorylation.
evidence:
- reference: PMID:28668382
reference_title: "Inflammation and mitochondrial dysfunction: A vicious circle in neurodegenerative disorders?"
supports: SUPPORT
evidence_source: OTHER
snippet: "Cytokines, particularly tumor necrosis factor-alpha, impede mitochondrial oxidative phosphorylation and associated ATP production and instigate mitochondrial reactive oxygen species production."
explanation: Demonstrates that inflammatory cytokines directly impair mitochondrial oxidative phosphorylation and ATP production.
- target: Mast Cell Activation
description: Immune dysregulation and elevated cytokines promote mast cell activation syndrome.
evidence:
- reference: PMID:37389095
reference_title: "Immunological dysfunction and mast cell activation syndrome in long COVID."
supports: SUPPORT
snippet: "There is an activated condition of mast cells in long COVID-19, with abnormal granulation and excessive inflammatory cytokine release."
explanation: Documents mast cell activation with abnormal granulation in the context of Long COVID immune dysregulation.
- target: Autonomic Nervous System Dysfunction
description: Systemic inflammation and immune-mediated damage disrupt autonomic nervous system function.
evidence:
- reference: PMID:37064029
reference_title: "A review of cytokine-based pathophysiology of Long COVID symptoms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "arthralgias, paresthesias, dysautonomia, and GI and ophthalmic problems can consequently arise as result of the elevated peripheral and central cytokines."
explanation: Explicitly links elevated cytokines to dysautonomia, supporting inflammation-driven autonomic dysfunction.
- target: Myalgia
description: Inflammatory cytokines cause widespread muscle pain.
evidence:
- reference: PMID:35295802
reference_title: "A Review: The Manifestations, Mechanisms, and Treatments of Musculoskeletal Pain in Patients With COVID-19."
supports: SUPPORT
snippet: "studies have shown that inflammatory cytokines could cause myalgia by inducing prostaglandin E2 (PGE2) production"
explanation: Provides the mechanistic link between inflammatory cytokines and myalgia via PGE2 induction in COVID-19.
- target: Arthralgia
description: Inflammatory cytokines drive joint pain without overt inflammation.
evidence:
- reference: PMID:37064029
reference_title: "A review of cytokine-based pathophysiology of Long COVID symptoms."
supports: SUPPORT
snippet: "arthralgias, paresthesias, dysautonomia, and GI and ophthalmic problems can consequently arise as result of the elevated peripheral and central cytokines."
explanation: Directly attributes arthralgias to elevated cytokine levels in Long COVID.
- name: T Cell Exhaustion and Tissue Trafficking
description: >
SARS-CoV-2-specific CD8+ T cells exhibit exhaustion phenotypes while CD4+ T
cells are poised to migrate to inflamed tissues, reflecting sustained antigen
exposure and chronic activation in Long COVID.
cell_types:
- preferred_term: CD4-positive T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: CD8-positive T cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
biological_processes:
- preferred_term: T cell migration
term:
id: GO:0072678
label: T cell migration
- preferred_term: T cell activation
term:
id: GO:0042110
label: T cell activation
evidence:
- reference: PMID:38212464
reference_title: "Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2."
supports: SUPPORT
snippet: "LC individuals displayed increased frequencies of CD4+ T cells poised to migrate to inflamed tissues and exhausted SARS-CoV-2-specific CD8+ T cells"
explanation: Documents tissue-trafficking CD4+ cells and exhausted virus-specific CD8+ cells in Long COVID.
- name: Endothelial Dysfunction and Microclots
description: >
Persistent endothelial damage and formation of amyloid-like fibrin microclots
impair microcirculation. These anomalous fibrin deposits resist normal fibrinolysis
and can block capillaries, limiting oxygen delivery to tissues and potentially
explaining the diverse symptomatology of Long COVID.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
- preferred_term: platelet
term:
id: CL:0000233
label: platelet
biological_processes:
- preferred_term: fibrinolysis
term:
id: GO:0042730
label: fibrinolysis
evidence:
- reference: PMID:35195253
reference_title: "A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications."
supports: SUPPORT
snippet: "The result, as is strongly manifested in platelet-poor plasma (PPP) of individuals with Long COVID, is extensive fibrin amyloid microclots that can persist, can entrap other proteins, and that may lead to the production of various autoantibodies."
explanation: Documents the presence and persistence of amyloid fibrin microclots in Long COVID patients.
- reference: PMID:35195253
reference_title: "A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications."
supports: SUPPORT
snippet: "the ability of these fibrin amyloid microclots (fibrinaloids) to block up capillaries, and thus to limit the passage of red blood cells and hence O2 exchange, can actually underpin the majority of these symptoms"
explanation: Explains how microclots may cause Long COVID symptoms through impaired oxygen delivery.
downstream:
- target: Impaired Mitochondrial Energy Production
description: Microclot-mediated capillary blockage impairs oxygen delivery, reducing mitochondrial oxidative phosphorylation.
evidence:
- reference: PMID:35195253
reference_title: "A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the ability of these fibrin amyloid microclots (fibrinaloids) to block up capillaries, and thus to limit the passage of red blood cells and hence O2 exchange, can actually underpin the majority of these symptoms"
explanation: Capillary obstruction with reduced oxygen exchange supports downstream mitochondrial energy impairment.
- target: Fatigue
description: Impaired microcirculatory oxygen exchange contributes to persistent fatigue.
evidence:
- reference: PMID:35195253
reference_title: "A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the ability of these fibrin amyloid microclots (fibrinaloids) to block up capillaries, and thus to limit the passage of red blood cells and hence O2 exchange, can actually underpin the majority of these symptoms"
explanation: Microvascular oxygen-delivery deficits are consistent with persistent fatigue symptom burden.
- target: Dyspnea
description: Reduced pulmonary capillary perfusion and oxygen delivery contribute to breathlessness.
evidence:
- reference: PMID:35195253
reference_title: "A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the ability of these fibrin amyloid microclots (fibrinaloids) to block up capillaries, and thus to limit the passage of red blood cells and hence O2 exchange, can actually underpin the majority of these symptoms"
explanation: Impaired O2 exchange from microclots supports a mechanistic basis for ongoing breathlessness.
- name: Serotonin Depletion Mechanisms
description: >
Long COVID features reduced peripheral serotonin driven by diminished
intestinal tryptophan absorption, platelet hyperactivation that depletes
stored serotonin, and enhanced monoamine oxidase-mediated serotonin
turnover.
biological_processes:
- preferred_term: tryptophan transport
term:
id: GO:0015827
label: tryptophan transport
- preferred_term: platelet activation
term:
id: GO:0030168
label: platelet activation
- preferred_term: serotonin metabolic process
term:
id: GO:0042428
label: serotonin metabolic process
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
snippet: "Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover."
explanation: Describes the three mechanistic drivers of serotonin loss in Long COVID.
downstream:
- target: Vagus-Hippocampal Signaling Impairment
description: Peripheral serotonin reduction impedes vagus nerve activity and impairs hippocampal signaling.
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory."
explanation: Direct evidence that serotonin depletion impairs vagal-hippocampal signaling.
- target: Autonomic Nervous System Dysfunction
description: Serotonin modulates autonomic tone; its depletion contributes to dysautonomia.
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory."
explanation: Supports serotonin-mediated vagal dysfunction; extension to broader dysautonomia is mechanistically consistent.
- target: Depression
description: Reduced serotonin levels contribute to depressed mood through classical monoamine mechanisms.
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Viral infection and type I interferon-driven inflammation reduce serotonin through three mechanisms: diminished intestinal absorption of the serotonin precursor tryptophan; platelet hyperactivation and thrombocytopenia, which impacts serotonin storage; and enhanced MAO-mediated serotonin turnover."
explanation: Establishes sustained serotonin depletion, a core mechanistic substrate for depressive symptoms.
- name: Vagus-Hippocampal Signaling Impairment
description: >
Peripheral serotonin depletion weakens vagus nerve activity, leading to
impaired hippocampal responses and memory formation that contribute to
cognitive symptoms in Long COVID.
biological_processes:
- preferred_term: regulation of synaptic plasticity
term:
id: GO:0048167
label: regulation of synaptic plasticity
- preferred_term: memory
term:
id: GO:0007613
label: memory
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
snippet: "Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory."
explanation: Connects serotonin loss to vagal signaling deficits and hippocampal dysfunction.
downstream:
- target: Neuroinflammation
description: Impaired vagal anti-inflammatory reflex permits unchecked neuroinflammation.
evidence:
- reference: PMID:38018736
reference_title: "Vagus nerve SARS-CoV-2 infection and inflammatory reflex dysfunction: Is there a causal relationship?"
supports: SUPPORT
snippet: "The vagus nerve inflammatory reflex is an important, well-characterized mechanism for the reflexive suppression of cytokine storm, and its experimental or clinical impairment facilitates the onset and progression of hyperinflammation."
explanation: Establishes that impairment of the vagal inflammatory reflex facilitates hyperinflammation.
- target: Cognitive Impairment
description: Disrupted hippocampal signaling impairs memory formation and cognitive function.
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory."
explanation: Directly connects vagal-hippocampal dysfunction to memory/cognitive impairment.
- name: Autonomic Nervous System Dysfunction
description: >
Dysautonomia, particularly postural orthostatic tachycardia syndrome (POTS),
develops in many Long COVID patients. This may be related to virus- or
immune-mediated disruption of the autonomic nervous system resulting in
orthostatic intolerance syndromes.
biological_processes:
- preferred_term: mast cell activation
term:
id: GO:0045576
label: mast cell activation
evidence:
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
snippet: "We posit that this condition may be related to a virus- or immune-mediated disruption of the autonomic nervous system resulting in orthostatic intolerance syndromes."
explanation: Proposes autonomic nervous system disruption as a key mechanism in Long COVID.
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
snippet: "'Post-acute COVID' (known colloquially as 'long COVID') is emerging as a prevalent syndrome. It encompasses a plethora of debilitating symptoms (including breathlessness, chest pain, palpitations and orthostatic intolerance)"
explanation: Documents the prevalence of autonomic symptoms in Long COVID.
downstream:
- target: Orthostatic Tachycardia
description: Autonomic dysfunction directly causes excessive heart rate increase upon standing.
evidence:
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We posit that this condition may be related to a virus- or immune-mediated disruption of the autonomic nervous system resulting in orthostatic intolerance syndromes."
explanation: Supports orthostatic tachycardia as a downstream manifestation of autonomic disruption.
- target: Palpitations
description: Dysautonomia produces awareness of abnormal heartbeat patterns.
evidence:
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "'Post-acute COVID' (known colloquially as 'long COVID') is emerging as a prevalent syndrome. It encompasses a plethora of debilitating symptoms (including breathlessness, chest pain, palpitations and orthostatic intolerance)"
explanation: Palpitations co-occur with orthostatic intolerance in post-acute COVID, supporting dysautonomia linkage.
- name: Impaired Mitochondrial Energy Production
description: >
Long COVID is associated with reduced mitochondrial ATP production and
impaired oxidative phosphorylation, contributing to fatigue, cognitive
disturbances, and exercise intolerance.
biological_processes:
- preferred_term: oxidative phosphorylation
term:
id: GO:0006119
label: oxidative phosphorylation
- preferred_term: ATP biosynthetic process
term:
id: GO:0006754
label: ATP biosynthetic process
evidence:
- reference: PMID:38668888
reference_title: "Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches."
supports: SUPPORT
snippet: "Emerging evidence has pointed to mitochondrial dysfunction as a potential underpinning mechanism contributing to the persistence and diversity of long COVID symptoms."
explanation: Links mitochondrial dysfunction and reduced energy production to persistent Long COVID symptoms.
downstream:
- target: Metabolic Shift and Oxidative Stress
description: Impaired oxidative phosphorylation forces a compensatory shift toward glycolysis with resulting oxidative stress.
evidence:
- reference: PMID:38668888
reference_title: "Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This review aims to synthesize current findings related to mitochondrial dysfunction in long COVID, exploring its implications for cellular energy deficits, oxidative stress, immune dysregulation, metabolic disturbances, and endothelial dysfunction."
explanation: Directly supports a downstream shift toward oxidative stress/metabolic disturbance from mitochondrial dysfunction.
- target: Fatigue
description: Reduced cellular ATP production underlies persistent fatigue.
evidence:
- reference: PMID:38668888
reference_title: "Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Emerging evidence has pointed to mitochondrial dysfunction as a potential underpinning mechanism contributing to the persistence and diversity of long COVID symptoms."
explanation: Supports mitochondrial dysfunction as a contributor to persistent fatigue in Long COVID.
- target: Post-exertional Malaise
description: Insufficient mitochondrial energy reserve causes symptom exacerbation after exertion.
evidence:
- reference: PMID:38668888
reference_title: "Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Emerging evidence has pointed to mitochondrial dysfunction as a potential underpinning mechanism contributing to the persistence and diversity of long COVID symptoms."
explanation: Supports energy-production deficits as a plausible driver of exertional symptom exacerbation.
- name: Metabolic Shift and Oxidative Stress
description: >
Mitochondrial impairment drives a shift toward glycolysis with associated
oxidative stress and metabolic disturbances, further exacerbating systemic
symptoms in Long COVID.
biological_processes:
- preferred_term: glycolytic process
term:
id: GO:0006096
label: glycolytic process
- preferred_term: response to oxidative stress
term:
id: GO:0006979
label: response to oxidative stress
evidence:
- reference: PMID:38668888
reference_title: "Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches."
supports: SUPPORT
snippet: "This review aims to synthesize current findings related to mitochondrial dysfunction in long COVID, exploring its implications for cellular energy deficits, oxidative stress, immune dysregulation, metabolic disturbances, and endothelial dysfunction."
explanation: Describes oxidative stress and metabolic disturbances resulting from mitochondrial dysfunction in Long COVID.
downstream:
- target: Impaired Mitochondrial Energy Production
description: Oxidative stress damages mitochondrial components, creating a self-reinforcing feedback loop of energy deficit.
evidence:
- reference: PMID:24557875
reference_title: "Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways."
supports: SUPPORT
evidence_source: OTHER
snippet: "Defects in ATP production and the electron transport complex, in turn, are associated with an elevated production of superoxide and hydrogen peroxide in mitochondria creating adaptive and synergistic damage."
explanation: Demonstrates the feedback loop where mitochondrial defects produce ROS that cause further synergistic damage.
- name: Mast Cell Activation
description: >
Mast cell activation syndrome (MCAS) has been implicated in Long COVID
pathophysiology. Mast cell degranulation releases pro-inflammatory mediators
including histamine, contributing to fatigue, brain fog, cardiovascular
symptoms, and gastrointestinal disturbances.
cell_types:
- preferred_term: mast cell
term:
id: CL:0000097
label: mast cell
evidence:
- reference: PMID:37529714
reference_title: "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation."
supports: SUPPORT
snippet: "Previous studies have suggested that mast cell activation (MCA) may play a role in the pathophysiology of long-COVID, including in the mechanisms of its cardiovascular manifestations."
explanation: Implicates mast cell activation in Long COVID pathophysiology.
- reference: PMID:37529714
reference_title: "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation."
supports: SUPPORT
snippet: "Long-COVID symptoms disappeared completely in 29% of treated patients. There was a significant improvement in each of the considered symptoms (improved or disappeared) in all treated patients"
explanation: Treatment response to antihistamines supports the role of mast cell activation in Long COVID.
downstream:
- target: Autonomic Nervous System Dysfunction
description: Histamine release from mast cells drives autonomic dysfunction and POTS symptoms.
evidence:
- reference: PMID:37951572
reference_title: "Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation."
supports: SUPPORT
evidence_source: OTHER
snippet: "MC are located perivascularly close to nerve endings and sites such as the carotid bodies, heart, hypothalamus, the pineal gland, and the adrenal gland that would allow them not only to regulate but also to be affected by the autonomic nervous system (ANS). MC are stimulated not only by allergens but also many other triggers including some from the ANS that can affect MC release of neurosensitizing, proinflammatory, and vasoactive mediators."
explanation: Establishes anatomical basis for mast cell regulation of autonomic nervous system at key control sites.
- target: Neuroinflammation
description: Mast cell mediators cross the blood-brain barrier and activate neuroinflammatory cascades.
evidence:
- reference: PMID:38638822
reference_title: "Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "These findings reveal a cellular mechanism of SARS-CoV-2-induced neuroinflammation."
explanation: Demonstrates mast-cell-mediated mechanisms for SARS-CoV-2-associated neuroinflammation.
- target: Tachycardia
description: Mast cell-derived histamine directly increases heart rate.
evidence:
- reference: PMID:37529714
reference_title: "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cardiovascular manifestations of long-COVID include high heart rate, postural tachycardia, and palpitations."
explanation: Supports tachycardia as a cardiovascular manifestation in the mast-cell-associated Long COVID phenotype.
- target: Diarrhea
description: Mast cell degranulation in the gastrointestinal tract causes diarrhea.
evidence:
- reference: PMID:15710782
reference_title: "Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "MCA+POTS patients were characterized by episodes of flushing, shortness of breath, headache, lightheadedness, excessive diuresis, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting."
explanation: Supports diarrhea as a downstream gastrointestinal manifestation of mast cell activation.
- target: Nausea
description: Gastrointestinal mast cell activation produces nausea.
evidence:
- reference: PMID:15710782
reference_title: "Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders."
supports: SUPPORT
snippet: "MCA+POTS patients were characterized by episodes of flushing, shortness of breath, headache, lightheadedness, excessive diuresis, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting."
explanation: Documents nausea as a characteristic symptom of mast cell activation in POTS patients.
- name: Neuroinflammation
description: >
Neuroinflammation in Long COVID involves microglial activation, blood-brain
barrier disruption, and inflammatory cytokine penetration into the brain
parenchyma. This contributes to cognitive dysfunction, memory impairment,
and other neurological symptoms.
cell_types:
- preferred_term: microglial cell
term:
id: CL:0000129
label: microglial cell
- preferred_term: macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:36846556
reference_title: "Long Covid brain fog: a neuroinflammation phenomenon?"
supports: SUPPORT
snippet: "Activation of microglia in response to an immune system challenge can lead to a significant impact on cognitive processes, such as learning, memory and emotional regulation."
explanation: Documents microglial activation and its impact on cognitive processes in Long COVID.
- reference: PMID:36846556
reference_title: "Long Covid brain fog: a neuroinflammation phenomenon?"
supports: SUPPORT
snippet: "Inflammatory cytokines have been found to play a significant role in reductions in LTP and LTD, a reduction in neurogenesis, and in dendritic sprouting."
explanation: Explains how inflammatory cytokines impair neural function in Long COVID brain fog.
downstream:
- target: Cognitive Impairment
description: Microglial activation and inflammatory cytokines impair learning, memory, and executive function.
evidence:
- reference: PMID:36846556
reference_title: "Long Covid brain fog: a neuroinflammation phenomenon?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Activation of microglia in response to an immune system challenge can lead to a significant impact on cognitive processes, such as learning, memory and emotional regulation."
explanation: Directly supports cognitive consequences of microglial activation in neuroinflammation.
- target: Headache
description: Neuroinflammatory mediators sensitize pain pathways and drive chronic headache.
evidence:
- reference: PMID:36284805
reference_title: "Unusual Presentation of COVID-19 Headache and Its Possible Pathomechanism."
supports: SUPPORT
snippet: "The possible COVID-19 pain pathway pathomechanism engaging interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF) alpha aided with a cortical spreading depression disturbing the hypothalamus is also described in this study."
explanation: Describes the neuroinflammatory cytokine pathway that produces headache pain in COVID-19.
- target: Depression
description: Inflammatory cytokines in the brain disrupt monoamine signaling and promote depressed mood.
evidence:
- reference: PMID:36846556
reference_title: "Long Covid brain fog: a neuroinflammation phenomenon?"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Activation of microglia in response to an immune system challenge can lead to a significant impact on cognitive processes, such as learning, memory and emotional regulation."
explanation: Supports mood/emotional dysregulation downstream of neuroinflammatory microglial activation.
- target: Anxiety
description: Neuroinflammation in limbic circuitry amplifies anxiety and emotional dysregulation.
evidence:
- reference: PMID:36846556
reference_title: "Long Covid brain fog: a neuroinflammation phenomenon?"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Activation of microglia in response to an immune system challenge can lead to a significant impact on cognitive processes, such as learning, memory and emotional regulation."
explanation: Supports anxiety-relevant emotional dysregulation as a downstream consequence of neuroinflammation.
differential_diagnoses:
- name: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
description: >
ME/CFS shares core symptoms with Long COVID, including fatigue, pain,
sleep disturbance, and cognitive dysfunction; emerging blood biomarkers
can help distinguish these conditions from post-COVID condition.
distinguishing_features:
- Blood variables including HERV-W ENV, cytokines, and anti-SARS-CoV-2 antibody profiles discriminated post-COVID condition from ME/CFS with high sensitivity and specificity.
- ME/CFS onset may predate the pandemic or lack confirmed SARS-CoV-2 infection, whereas post-COVID cases follow documented infection.
disease_term:
preferred_term: Myalgic encephalomyelitis/chronic fatigue syndrome
term:
id: MONDO:0005404
label: myalgic encephalomeyelitis/chronic fatigue syndrome
evidence:
- reference: PMID:40726775
reference_title: "Blood parameters differentiate post COVID-19 condition from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia."
supports: SUPPORT
snippet: "some of the measured variables showed a capacity to discriminate post-COVID-19 condition cases from all other participants, with 100 % sensitivity and up to 71.9 % specificity providing a new tool for a differential diagnosis between diseases or syndromes with so many overlapping clinical symptoms."
explanation: Demonstrates blood parameter signatures that separate post-COVID condition from ME/CFS despite overlapping symptoms.
- name: Fibromyalgia
description: >
Fibromyalgia overlaps with Long COVID on fatigue, pain, sleep disturbance,
and cognitive symptoms; biomarker panels can aid differentiation from
post-COVID condition.
distinguishing_features:
- Blood variables including HERV-W ENV, cytokines, and anti-SARS-CoV-2 antibody profiles discriminated post-COVID condition from fibromyalgia with high sensitivity and specificity.
- Fibromyalgia lacks the post-viral timing linked to confirmed SARS-CoV-2 infection.
disease_term:
preferred_term: Fibromyalgia
term:
id: MONDO:0005546
label: fibromyalgia
evidence:
- reference: PMID:40726775
reference_title: "Blood parameters differentiate post COVID-19 condition from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia."
supports: SUPPORT
snippet: "some of the measured variables showed a capacity to discriminate post-COVID-19 condition cases from all other participants, with 100 % sensitivity and up to 71.9 % specificity providing a new tool for a differential diagnosis between diseases or syndromes with so many overlapping clinical symptoms."
explanation: Shows biomarker-driven differentiation between post-COVID condition and fibromyalgia.
- name: Narcolepsy Type II
description: >
Excessive daytime sleepiness after COVID-19 may reflect narcolepsy type II
rather than Long COVID; identifying narcolepsy avoids misattribution of
hypersomnolence to post-viral fatigue alone.
distinguishing_features:
- Multiple sleep latency testing with shortened sleep latencies and sleep-onset REM periods indicates narcolepsy.
- Symptoms can remit with immunomodulatory therapy, differentiating from typical Long COVID fatigue courses.
disease_term:
preferred_term: narcolepsy without cataplexy
term:
id: MONDO:0019371
label: narcolepsy without cataplexy
evidence:
- reference: PMID:39622313
reference_title: "Corticosteroid-responsive narcolepsy type II after COVID-19: A relevant differential diagnosis of post-COVID syndrome (a case report)."
supports: SUPPORT
snippet: "A diagnosis of narcolepsy type II was made based on pathologically shortened sleep latencies in polysomnography and multiple sleep latency tests (MSLT) together with several sleep-onset REM-sleep periods (SOREMs)."
explanation: Provides diagnostic sleep study criteria distinguishing narcolepsy from Long COVID-related sleepiness.
- name: Post-COVID-19 Vaccination Syndrome
description: >
Mental symptoms such as fatigue, cognitive problems, and sleep disturbance
can occur after vaccination without infection, creating overlap with Long
COVID symptom profiles.
distinguishing_features:
- Onset follows vaccination without documented SARS-CoV-2 infection; symptom prevalence varies by dose number and vaccine type.
- PCVS cases showed similar overall prevalence but different age and vaccination-pattern associations compared with post-infection cases.
evidence:
- reference: PMID:40832032
reference_title: "Mental symptoms in post-COVID syndrome and post-COVID-19 vaccination syndrome: results of a representative population survey."
supports: SUPPORT
snippet: "The prevalence of self-reported mental symptoms of PCS was 12.1%... The prevalence of self-reported PCVS was 12.6% among vaccinated individuals"
explanation: Shows overlapping mental symptom prevalence after vaccination alone, underscoring the need to distinguish PCVS from infection-related Long COVID.
- name: Persistent SARS-CoV-2 Infection in Immunocompromised Hosts
description: >
In immunocompromised patients, prolonged fever or symptoms may reflect
persistent SARS-CoV-2 infection rather than post-acute sequelae, and should
be ruled out before labeling Long COVID.
distinguishing_features:
- Fever of unknown origin with B-cell depletion or other immunosuppression warrants direct viral testing for ongoing infection.
- Persistent viral shedding may present without classic acute symptoms but resolves with targeted infection management.
disease_term:
preferred_term: COVID-19
term:
id: MONDO:0100096
label: COVID-19
evidence:
- reference: PMID:41384162
reference_title: "Expanding the causes of Fever of Unknown Origin in immunocompromised patients: report of two cases highlighting the role of SARS-CoV-2."
supports: SUPPORT
snippet: "We report two cases of long-lasting fever in patients with multiple sclerosis and B-cell depletion, finally diagnosed as COVID-19. We suggest the inclusion of SARS-CoV-2 testing in the differential diagnosis of FUO."
explanation: Illustrates how persistent infection can mimic post-COVID presentations in immunocompromised patients and must be excluded.
phenotypes:
- name: Fatigue
description: Persistent, debilitating fatigue that is not relieved by rest.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias, post-exertional malaise, orthostatic intolerance and other symptoms that greatly interfere with their ability to function"
explanation: Documents fatigue as a prominent symptom that interferes with function in Long COVID.
- name: Cognitive Impairment
description: >
Brain fog, difficulty concentrating, memory problems, and reduced
executive function. Often referred to as cognitive dysfunction.
phenotype_term:
preferred_term: Memory impairment
term:
id: HP:0002354
label: Memory impairment
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep"
explanation: Documents cognitive problems as a core symptom of Long COVID.
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
snippet: "Peripheral serotonin reduction, in turn, impedes the activity of the vagus nerve and thereby impairs hippocampal responses and memory."
explanation: Provides mechanistic explanation for memory impairment in Long COVID.
- name: Dyspnea
description: Shortness of breath and breathing difficulties persisting after acute infection.
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
evidence:
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
snippet: "It encompasses a plethora of debilitating symptoms (including breathlessness, chest pain, palpitations and orthostatic intolerance)"
explanation: Lists breathlessness (dyspnea) among the debilitating symptoms of Long COVID.
- name: Post-exertional Malaise
description: >
Worsening of symptoms following physical or mental exertion,
similar to myalgic encephalomyelitis/chronic fatigue syndrome.
phenotype_term:
preferred_term: Post-exertional malaise
term:
id: HP:0030973
label: Postexertional symptom exacerbation
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias, post-exertional malaise, orthostatic intolerance"
explanation: Explicitly identifies post-exertional malaise as a core Long COVID symptom.
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "The illness (Long COVID) is similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)"
explanation: Notes the similarity between Long COVID and ME/CFS, which share post-exertional malaise.
sequelae:
- target: Fatigue
description: Episodes of post-exertional malaise exacerbate and prolong baseline fatigue.
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias, post-exertional malaise, orthostatic intolerance and other symptoms that greatly interfere with their ability to function"
explanation: Co-occurrence of post-exertional malaise with persistent fatigue supports exacerbation of fatigue burden.
- name: Palpitations
description: Awareness of heartbeat, often associated with POTS or general autonomic dysfunction.
phenotype_term:
preferred_term: Palpitations
term:
id: HP:0001962
label: Palpitations
evidence:
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
snippet: "It encompasses a plethora of debilitating symptoms (including breathlessness, chest pain, palpitations and orthostatic intolerance)"
explanation: Lists palpitations among the debilitating symptoms of Long COVID.
- reference: PMID:37529714
reference_title: "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation."
supports: SUPPORT
snippet: "Cardiovascular manifestations of long-COVID include high heart rate, postural tachycardia, and palpitations."
explanation: Confirms palpitations as a cardiovascular manifestation of Long COVID.
- name: Tachycardia
description: Elevated heart rate, often associated with POTS or general autonomic dysfunction.
phenotype_term:
preferred_term: Tachycardia
term:
id: HP:0001649
label: Tachycardia
evidence:
- reference: PMID:37529714
reference_title: "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation."
supports: SUPPORT
snippet: "Cardiovascular manifestations of long-COVID include high heart rate, postural tachycardia, and palpitations."
explanation: Documents high heart rate and postural tachycardia as Long COVID manifestations.
- name: Chest Pain
description: Persistent chest discomfort or pain.
phenotype_term:
preferred_term: Chest pain
term:
id: HP:0100749
label: Chest pain
evidence:
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
snippet: "It encompasses a plethora of debilitating symptoms (including breathlessness, chest pain, palpitations and orthostatic intolerance)"
explanation: Lists chest pain among the debilitating symptoms of Long COVID.
- name: Headache
description: Chronic or recurring headaches.
phenotype_term:
preferred_term: Headache
term:
id: HP:0002315
label: Headache
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep"
explanation: Lists headaches among the persistent symptoms following COVID-19.
- name: Sleep Disturbance
description: Insomnia, unrefreshing sleep, or altered sleep patterns.
phenotype_term:
preferred_term: Sleep disturbance
term:
id: HP:0002360
label: Sleep disturbance
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep"
explanation: Documents disrupted sleep as a symptom that interferes with function.
sequelae:
- target: Cognitive Impairment
description: Sleep disruption impairs memory consolidation and executive function.
evidence:
- reference: PMID:38370438
reference_title: "Impact of sleep disruption on cognitive function in patients with postacute sequelae of SARS-CoV-2 infection: initial findings from a Neuro-COVID-19 clinic."
supports: SUPPORT
snippet: "Objective evidence of sleep disruption measured by wakefulness after sleep onset, sleep efficiency, and latency were associated with decreased performance in attention and processing speed."
explanation: Demonstrates objective sleep disruption metrics predict decreased cognitive performance in Long COVID patients.
- name: Anxiety
description: Increased anxiety levels and panic symptoms.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
evidence:
- reference: PMID:38321404
reference_title: "The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis."
supports: SUPPORT
snippet: "The pooled prevalence of depression and anxiety among patients coping with Post COVID-19 syndrome was estimated to be 23% (95% CI: 20%-26%; I2 = 99.9%) based on data from 143 studies with 7,782,124 participants and 132 studies with 9,320,687 participants, respectively."
explanation: Meta-analysis establishes 23% prevalence of anxiety in Long COVID patients.
- reference: PMID:38231397
reference_title: "Anxiety and depression symptoms among patients with long COVID: a retrospective cohort study."
supports: SUPPORT
snippet: "Patients suffering from post-acute sequelae of COVID-19 (PASC) have a higher prevalence of anxiety and depression than the general population."
explanation: Documents higher prevalence of anxiety in PASC patients compared to general population.
- name: Depression
description: Depressed mood and emotional dysregulation.
phenotype_term:
preferred_term: Depression
term:
id: HP:0000716
label: Depression
evidence:
- reference: PMID:38321404
reference_title: "The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis."
supports: SUPPORT
snippet: "The pooled prevalence of depression and anxiety among patients coping with Post COVID-19 syndrome was estimated to be 23% (95% CI: 20%-26%; I2 = 99.9%) based on data from 143 studies with 7,782,124 participants"
explanation: Meta-analysis establishes 23% prevalence of depression in Long COVID patients.
- reference: PMID:38231397
reference_title: "Anxiety and depression symptoms among patients with long COVID: a retrospective cohort study."
supports: SUPPORT
snippet: "Overall, patients with PASC may have experienced a heavier burden of newly manifest anxiety and depression symptoms compared to patients seen in the GIM clinic."
explanation: Documents higher burden of newly manifest depression in Long COVID patients.
- name: Anosmia
description: Loss or alteration of sense of smell persisting beyond acute infection.
phenotype_term:
preferred_term: Anosmia
term:
id: HP:0000458
label: Anosmia
evidence:
- reference: PMID:38976065
reference_title: "The long-term effect of COVID-19 infection on olfaction and taste; a prospective analysis."
supports: SUPPORT
snippet: "During the acute-phase of COVID-19, 80% of patients reported anosmia, 15% hyposmia, 63% ageusia, and 33% hypogeusia. At two years' follow-up, 53% still experienced smell impairment"
explanation: Documents persistent anosmia with 53% still affected at 2-year follow-up.
- reference: PMID:38976065
reference_title: "The long-term effect of COVID-19 infection on olfaction and taste; a prospective analysis."
supports: SUPPORT
snippet: "Most patients who initially suffered from smell and/or taste disturbance did not reach full recovery after 2 years follow-up."
explanation: Demonstrates long-term persistence of olfactory dysfunction in Long COVID.
- name: Ageusia
description: Loss or alteration of sense of taste.
phenotype_term:
preferred_term: Ageusia
term:
id: HP:0041051
label: Ageusia
evidence:
- reference: PMID:38976065
reference_title: "The long-term effect of COVID-19 infection on olfaction and taste; a prospective analysis."
supports: SUPPORT
snippet: "During the acute-phase of COVID-19, 80% of patients reported anosmia, 15% hyposmia, 63% ageusia, and 33% hypogeusia. At two years' follow-up, 53% still experienced smell impairment, and 42% suffered from taste impairment."
explanation: Documents persistent ageusia with 42% still affected at 2-year follow-up.
- name: Myalgia
description: Muscle pain and body aches.
phenotype_term:
preferred_term: Myalgia
term:
id: HP:0003326
label: Myalgia
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias"
explanation: Lists myalgias as a persistent symptom of Long COVID.
- name: Arthralgia
description: Joint pain without inflammation.
phenotype_term:
preferred_term: Arthralgia
term:
id: HP:0002829
label: Arthralgia
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias"
explanation: Lists arthralgias as a persistent symptom of Long COVID.
- name: Orthostatic Tachycardia
description: Excessive heart rate increase upon standing, characteristic of POTS.
phenotype_term:
preferred_term: Orthostatic tachycardia
term:
id: HP:0012173
label: Orthostatic tachycardia
evidence:
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
snippet: "They develop persistent fatigue, cognitive problems, headaches, disrupted sleep, myalgias and arthralgias, post-exertional malaise, orthostatic intolerance"
explanation: Documents orthostatic intolerance among Long COVID symptoms.
- reference: PMID:33243837
reference_title: "Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies."
supports: SUPPORT
snippet: "It encompasses a plethora of debilitating symptoms (including breathlessness, chest pain, palpitations and orthostatic intolerance)"
explanation: Documents orthostatic intolerance as a debilitating Long COVID symptom.
- name: Cough
description: Persistent cough continuing beyond acute infection.
phenotype_term:
preferred_term: Cough
term:
id: HP:0012735
label: Cough
evidence:
- reference: PMID:34839263
reference_title: "Characterizing Long COVID: Deep Phenotype of a Complex Condition."
supports: SUPPORT
snippet: "curated 59 relevant manuscripts that described clinical manifestations in 81 cohorts three weeks or more following acute COVID-19, and mapped 287 unique clinical findings to HPO terms"
explanation: Systematic review identifying cough among the 287 clinical manifestations mapped to HPO terms in Long COVID.
- name: Pulmonary Opacity
description: Ground glass opacification or other pulmonary imaging abnormalities persisting after acute infection.
phenotype_term:
preferred_term: Pulmonary opacity
term:
id: HP:0031457
label: Pulmonary opacity
evidence:
- reference: PMID:34839263
reference_title: "Characterizing Long COVID: Deep Phenotype of a Complex Condition."
supports: SUPPORT
snippet: "curated 59 relevant manuscripts that described clinical manifestations in 81 cohorts three weeks or more following acute COVID-19, and mapped 287 unique clinical findings to HPO terms"
explanation: Systematic review documenting pulmonary imaging findings including ground glass opacity in Long COVID.
- name: Insomnia
description: Difficulty falling asleep or staying asleep.
phenotype_term:
preferred_term: Insomnia
term:
id: HP:0100785
label: Insomnia
evidence:
- reference: PMID:34839263
reference_title: "Characterizing Long COVID: Deep Phenotype of a Complex Condition."
supports: SUPPORT
snippet: "Across at least 10 cohorts, authors reported 31 unique clinical features corresponding to HPO terms; the most commonly reported feature was Fatigue (median 45.1%)"
explanation: Insomnia was among the 31 most commonly reported clinical features across Long COVID cohorts.
sequelae:
- target: Anxiety
description: Chronic insomnia is a significant predictor for the onset of anxiety.
evidence:
- reference: PMID:30537570
reference_title: "Insomnia as a predictor of mental disorders: A systematic review and meta-analysis."
supports: SUPPORT
snippet: "insomnia is a significant predictor for the onset of depression (10 studies, OR 2.83, CI 1.55-5.17), anxiety (six studies, OR 3.23, CI 1.52-6.85)"
explanation: Meta-analysis establishes insomnia as a significant predictor for anxiety onset with OR 3.23.
- target: Depression
description: Persistent insomnia is a significant risk factor for the development of depression.
evidence:
- reference: PMID:27816065
reference_title: "Insomnia and the risk of depression: a meta-analysis of prospective cohort studies."
supports: SUPPORT
snippet: "insomnia is significantly associated with an increased risk of depression"
explanation: Meta-analysis of 34 cohort studies with 172,077 participants shows insomnia increases depression risk (RR 2.27).
- name: Diarrhea
description: Loose or watery bowel movements persisting after acute infection.
phenotype_term:
preferred_term: Diarrhea
term:
id: HP:0002014
label: Diarrhea
evidence:
- reference: PMID:34839263
reference_title: "Characterizing Long COVID: Deep Phenotype of a Complex Condition."
supports: SUPPORT
snippet: "curated 59 relevant manuscripts that described clinical manifestations in 81 cohorts three weeks or more following acute COVID-19, and mapped 287 unique clinical findings to HPO terms"
explanation: Gastrointestinal symptoms including diarrhea were among the clinical manifestations mapped in Long COVID.
- name: Nausea
description: Sensation of unease in the stomach with urge to vomit.
phenotype_term:
preferred_term: Nausea
term:
id: HP:0002018
label: Nausea
evidence:
- reference: PMID:34839263
reference_title: "Characterizing Long COVID: Deep Phenotype of a Complex Condition."
supports: SUPPORT
snippet: "the most commonly reported feature was Fatigue (median 45.1%) and the least commonly reported was Nausea (median 3.9%)"
explanation: Nausea was reported across multiple Long COVID cohorts with median prevalence of 3.9%.
biochemical:
- name: Serotonin Deficiency
notes: >
Reduced peripheral serotonin levels due to decreased tryptophan absorption,
platelet hyperactivation, and increased MAO-mediated turnover.
evidence:
- reference: PMID:37848036
reference_title: "Serotonin reduction in post-acute sequelae of viral infection."
supports: SUPPORT
snippet: "We find that PASC are associated with serotonin reduction."
explanation: Directly establishes serotonin reduction as associated with Long COVID.
- name: Elevated Inflammatory Cytokines
notes: >
Persistently elevated pro-inflammatory cytokines including IL-6, TNF-alpha,
and type I interferons contribute to systemic inflammation.
evidence:
- reference: PMID:38212464
reference_title: "Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2."
supports: SUPPORT
snippet: "LC individuals exhibited systemic inflammation and immune dysregulation."
explanation: Documents systemic inflammation in Long COVID patients.
treatments:
- name: Activity pacing
description: >
Structured energy-envelope management to reduce post-exertional symptom
exacerbation.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
target_phenotypes:
- preferred_term: Post-exertional malaise
term:
id: HP:0030973
label: Postexertional symptom exacerbation
- preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: PMID:38658496
reference_title: "Practical Recommendations for Exercise Training in Patients with Long COVID with or without Post-exertional Malaise: A Best Practice Proposal."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "clinical experience has shown that the presence of post-exertional malaise (PEM) is a significant barrier to physical exercise training in people with long COVID."
explanation: Supports pacing as a prerequisite strategy when PEM limits standard exercise progression.
- reference: PMID:37342500
reference_title: "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The illness (Long COVID) is similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)"
explanation: Supports borrowing pacing-based management approaches from ME/CFS care models.
- name: Individualized physical exercise therapy
description: >
Personalized exercise-based physical therapy with intensity adjusted to PEM
severity and tolerance.
treatment_term:
preferred_term: physical therapy
term:
id: MAXO:0000011
label: physical therapy
target_phenotypes:
- preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
evidence:
- reference: PMID:38658496
reference_title: "Practical Recommendations for Exercise Training in Patients with Long COVID with or without Post-exertional Malaise: A Best Practice Proposal."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "impaired exercise performance is a condition that can be recovered in many people through an individualized physical exercise training program."
explanation: Supports individualized exercise therapy as an effective rehabilitation component.
- reference: PMID:37061399
reference_title: "Long COVID and rehabilitation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Rehabilitation is a key element of management to achieve functional improvement... Exercise-based therapy, an essential part of management of long COVID, can be conducted with different modules, including telerehabilitation."
explanation: Confirms exercise-based physical rehabilitation as a core management pillar.
- name: Antihistamine Therapy
description: >
H1 and H2 receptor antagonists (such as fexofenadine and famotidine)
to address mast cell activation symptoms.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
qualifiers:
- predicate:
preferred_term: therapeutic agent
term:
id: NCIT:C2259
label: Therapeutic Agent
value:
preferred_term: histamine antagonist
term:
id: CHEBI:37956
label: histamine antagonist
- predicate:
preferred_term: therapeutic agent
term:
id: NCIT:C2259
label: Therapeutic Agent
value:
preferred_term: fexofenadine
term:
id: CHEBI:5050
label: fexofenadine
- predicate:
preferred_term: therapeutic agent
term:
id: NCIT:C2259
label: Therapeutic Agent
value:
preferred_term: famotidine
term:
id: CHEBI:4975
label: famotidine
target_phenotypes:
- preferred_term: Tachycardia
term:
id: HP:0001649
label: Tachycardia
- preferred_term: Palpitations
term:
id: HP:0001962
label: Palpitations
evidence:
- reference: PMID:37529714
reference_title: "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Patients were treated with fexofenadine (180 mg/day) and famotidine (40 mg/day). Fatigue, brain fog, abdominal disorders, and increased heart rate were evaluated in treated and untreated patients at baseline and 20 days later."
explanation: Details the antihistamine treatment protocol used in Long COVID.
- reference: PMID:37529714
reference_title: "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Long-COVID symptoms disappeared completely in 29% of treated patients. There was a significant improvement in each of the considered symptoms"
explanation: Documents significant improvement with antihistamine treatment.
- name: Ivabradine therapy for post-COVID POTS-like tachycardia
description: >
Heart-rate-lowering pharmacotherapy for Long-COVID patients with orthostatic
tachycardia syndromes.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
qualifiers:
- predicate:
preferred_term: therapeutic agent
term:
id: NCIT:C2259
label: Therapeutic Agent
value:
preferred_term: ivabradine
term:
id: CHEBI:85966
label: ivabradine
target_phenotypes:
- preferred_term: Orthostatic tachycardia
term:
id: HP:0012173
label: Orthostatic tachycardia
- preferred_term: Tachycardia
term:
id: HP:0001649
label: Tachycardia
evidence:
- reference: PMID:37469536
reference_title: "Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "43 of 55 (78%) of the included patients reported significant improvement of the symptoms within 7 days of ivabradine therapy."
explanation: Prospective post-COVID POTS study supports short-term symptom improvement with ivabradine.
- reference: PMID:39882369
reference_title: "Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Ivabradine, midodrine, and beta-blockers currently appear to be reasonable front-line choices in pharmacologic management of POTS (PASC associated and otherwise)."
explanation: Systematic review supports ivabradine among front-line options in PASC-associated POTS contexts.
- name: Beta adrenergic agent therapy for POTS-associated symptoms
description: >
Class-level beta-blocker therapy to reduce orthostatic tachycardia and
palpitations in Long-COVID dysautonomia phenotypes.
treatment_term:
preferred_term: beta adrenergic agent therapy
term:
id: MAXO:0000186
label: beta adrenergic agent therapy
target_phenotypes:
- preferred_term: Orthostatic tachycardia
term:
id: HP:0012173
label: Orthostatic tachycardia
- preferred_term: Palpitations
term:
id: HP:0001962
label: Palpitations
evidence:
- reference: PMID:39882369
reference_title: "Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Ivabradine, midodrine, and beta-blockers currently appear to be reasonable front-line choices in pharmacologic management of POTS (PASC associated and otherwise)."
explanation: Supports beta-blockers as reasonable front-line therapy in PASC-associated POTS, while acknowledging ongoing evidence development.
- name: Hyperbaric oxygen therapy
description: >
Adjunctive therapy under pressure-controlled oxygen conditions, studied for
fatigue, cognitive, neuropsychiatric, and cardiopulmonary Long-COVID symptoms.
treatment_term:
preferred_term: therapy
term:
id: MAXO:0001298
label: therapy
qualifiers:
- predicate:
preferred_term: therapeutic agent
term:
id: NCIT:C2259
label: Therapeutic Agent
value:
preferred_term: Hyperbaric Oxygen
term:
id: NCIT:C2351
label: Hyperbaric Oxygen
target_phenotypes:
- preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- preferred_term: Memory impairment
term:
id: HP:0002354
label: Memory impairment
evidence:
- reference: PMID:41745098
reference_title: "Hyperbaric Oxygen Therapy on Long COVID Symptoms: A Breath of Fresh Air."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "They suggested that HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms and cardiopulmonary functions."
explanation: Literature synthesis suggests multi-domain symptomatic benefit, but indicates need for larger definitive studies.
- reference: PMID:41745098
reference_title: "Hyperbaric Oxygen Therapy on Long COVID Symptoms: A Breath of Fresh Air."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "HBOT is a safe treatment and has shown some benefits for long COVID symptoms."
explanation: Supports safety and preliminary benefit signal for HBOT in Long COVID.
- name: Intranasal and transcranial photobiomodulation
description: >
Non-invasive light-based intervention studied for post-COVID cognitive
dysfunction (brain fog).
treatment_term:
preferred_term: therapy
term:
id: MAXO:0001298
label: therapy
qualifiers:
- predicate:
preferred_term: therapeutic agent
term:
id: NCIT:C2259
label: Therapeutic Agent
value:
preferred_term: Phototherapy
term:
id: NCIT:C15301
label: Phototherapy
target_phenotypes:
- preferred_term: Memory impairment
term:
id: HP:0002354
label: Memory impairment
evidence:
- reference: PMID:41768981
reference_title: "Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trial."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Home-based itPBM is safe and feasible, showing potential cognitive benefits for PCC brain fog, particularly in younger adults."
explanation: Pilot randomized evidence supports feasibility/safety and signals cognitive benefit requiring confirmation in larger trials.
notes: >
Long COVID shares substantial clinical and biological overlap with myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS) and postural orthostatic
tachycardia syndrome (POTS). Risk factors for developing Long COVID include
female sex, type 2 diabetes, pre-existing autoimmune conditions, and evidence
of EBV reactivation during acute infection. The condition can occur following
both mild and severe acute illness and may present as a relapsing-remitting
course with new symptoms emerging months to years after initial infection.
datasets:
- accession: geo:GSE270045
title: Upregulation of olfactory receptors and neuronal-associated genes highlights complex immune and neuronal dysregulation in Long COVID patients
description: >
GEO bulk transcriptomic dataset paired with immune and hormonal profiling
in long COVID patients meeting ME/CFS criteria, highlighting sex-specific
dysregulation.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: BULK_RNA_SEQ
conditions:
- Long COVID with ME/CFS
platform: GEO
publication: PMID:41205594
evidence:
- reference: PMID:41205594
reference_title: "Integrated immune, hormonal, and transcriptomic profiling reveals sex-specific dysregulation in long COVID patients with ME/CFS."
supports: SUPPORT
snippet: "Integrated immune, hormonal, and transcriptomic profiling reveals sex-specific dysregulation in long COVID patients with ME/CFS."
explanation: Links the dataset to sex-specific transcriptomic and immune profiling in long COVID with ME/CFS.
notes: "Dataset record: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270045"
clinical_trials:
- name: NCT06452082
phase: NOT_APPLICABLE
status: RECRUITING
description: Retrospective observational study evaluating the effect of vitamin D3 supplementation in reducing the risk of developing Long COVID syndrome after acute COVID-19 illness and in reducing the risk of SARS-CoV-2 infection after vaccination.
target_phenotypes:
- preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: clinicaltrials:NCT06452082
supports: SUPPORT
snippet: "The aim of this observational retrospective study is to evaluate the effect of supplementation with cholecalciferol D3 in reducing the risk of occurence of Long COVID syndrome after acute COVID-19 illness"
explanation: This trial directly investigates interventions to prevent Long COVID development, providing clinical evidence for potential preventive strategies in post-viral syndrome management.